Appendix: Authoritative Resources


- Additional Resources
A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States

Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Part 1: Immunization of Infants, Children, and Adolescents

MMWR WITH ERRATA CORRECTIONS
This document incorporates the errata published by CDC in MMWR on February 17, 2006, and December 7, 2007. Corrections have been made to text and tables appearing on pages numbered (at the top) 2, 8, 9, 27, 28, and 29 of this document.

The original report is available online at www.cdc.gov/mmwr/pdf/rr/rr5416.pdf.

YELLOW HIGHLIGHTING ADDED TO ORIGINAL ARTICLE
Certain information in this document has been highlighted in yellow, because it provides precise guidance for administration of hepatitis B vaccine to all newborns at birth, prior to hospital discharge.

Hepatitis B:
What Hospitals Need to Do to Protect Newborns
www.immunize.org/protect-newborns
The MMWR series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

SUGGESTED CITATION
Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP); Part 1: Immunization of Infants, Children, and Adolescents. MMWR 2005;54(No. RR-16):[inclusive page numbers].

CONTENTS
Strategy to Eliminate Hepatitis B Virus Transmission ............ 1
Major Updates to the Recommendations ............................. 2
Background ...................................................................... 3
Prophylaxis Against HBV Infection ...................................... 7
Vaccination Schedules and Results of Vaccination ............ 7
Vaccine Safety .................................................................. 11
Future Considerations ................................................... 12
Recommendations for Hepatitis B Vaccination
of Infants, Children, and Adolescents ............................... 12
References .................................................................... 18
Appendices .................................................................... 25
Glossary ....................................................................... 32
Continuing Education Activity ......................................... CE-1

Disclosure of Relationship
CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

On the cover: Persons depicted in these materials are models and used for illustrative purposes only.
A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States

Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents

Prepared by
Eric E. Mast, MD1, Harold S. Margolis, MD,1 Anthony E. Fiore, MD,1 Edward W. Brink, MD,2 Susan T. Goldstein, MD,1 Susan A. Wang, MD,1 Linda A. Moyer,1 Beth P. Bell, MD,1 Miriam J. Alter, PhD1
1Division of Viral Hepatitis, National Center for Infectious Diseases, 2Immunization Services Division, National Immunization Program

Summary

This report is the first of a two-part statement from the Advisory Committee on Immunization Practices (ACIP) that updates the strategy to eliminate hepatitis B virus (HBV) transmission in the United States. The report provides updated recommendations to improve prevention of perinatal and early childhood HBV transmission, including implementation of universal infant vaccination beginning at birth, and to increase vaccine coverage among previously unvaccinated children and adolescents. Strategies to enhance implementation of the recommendations include 1) establishing standing orders for administration of hepatitis B vaccination beginning at birth; 2) instituting delivery hospital policies and procedures and case management programs to improve identification of and administration of immunoprophylaxis to infants born to mothers who are hepatitis B surface antigen (HBsAg) positive and to mothers with unknown HBsAg status at the time of delivery; and 3) implementing vaccination record reviews for all children aged 11–12 years and children and adolescents aged <19 years who were born in countries with intermediate and high levels of HBV endemicity, adopting hepatitis B vaccine requirements for school entry, and integrating hepatitis B vaccination services into settings that serve adolescents. The second part of the ACIP statement, which will include updated recommendations and strategies to increase hepatitis B vaccination of adults, will be published separately.

Strategy to Eliminate Hepatitis B Virus Transmission

Hepatitis B virus (HBV) is a bloodborne and sexually transmitted virus. Rates of new infection and acute disease are highest among adults, but chronic infection is more likely to occur in persons infected as infants or young children. Before hepatitis B vaccination programs became routine in the United States, an estimated 30%–40% of chronic infections are believed to have resulted from perinatal or early childhood transmission, even though <10% of reported cases of hepatitis B occurred in children aged <10 years (7). Chronically infected persons are at increased lifetime risk for cirrhosis and hepatocellular carcinoma (HCC) and also serve as the main reservoir for continued HBV transmission.

Hepatitis B vaccination is the most effective measure to prevent HBV infection and its consequences. Since they were first issued in 1982, recommendations for hepatitis B vaccination have evolved into a comprehensive strategy to eliminate HBV transmission in the United States (2–6) (Box 1). A primary focus of this strategy is universal vaccination of infants to prevent early childhood HBV infection and to eventually protect adolescents and adults from infection. Other components include routine screening of all pregnant women for hepatitis B surface antigen (HBsAg) and postexposure immunoprophylaxis of infants born to HBsAg-positive women, vaccination of children and adolescents who were not previously vaccinated, and vaccination of unvaccinated adults at increased risk for infection.

To date, the immunization strategy has been implemented with considerable success. Recent estimates indicate that >95% of pregnant women are tested for HBsAg, and case management has been effective in ensuring high levels of initiation and completion of postexposure immunoprophylaxis among identified infants born to HBsAg-positive women (7). Hepatitis B vaccine has been successfully integrated into the childhood vaccine schedule, and infant vaccine coverage levels are now equivalent to those of other vaccines in the childhood schedule. During 1990–2004, incidence of acute hepatitis B
in the United States declined 75%. The greatest decline (94%) occurred among children and adolescents, coincident with an increase in hepatitis B vaccine coverage. As of 2004, among U.S. children aged 19–35 months, >92% had been fully vaccinated with 3 doses of hepatitis B vaccine (6). This success can be attributed in part to the established infrastructure for vaccine delivery to children and to federal support for perinatal hepatitis B prevention programs.

Vaccine coverage among adolescents has also increased substantially. Preliminary data demonstrate that 50%–60% of adolescents aged 13–15 years have records indicating vaccination (with 3 doses) against hepatitis B (CDC, unpublished data, 2003). As of November 2005, a total of 34 states require vaccination for middle-school entry (9). Certain programs provide hepatitis B vaccine to youth who engage in behaviors that place them at high risk for HBV infection (i.e., injection-drug use, having more than one sex partner, and male sexual activity with other males), and adolescent hepatitis B vaccination is included as a Health Plan Employer Data Information Set (HEDIS) measure (10).

Despite these successes, challenges remain. Even with improvements in the management of pregnant women, only approximately 50% of expected births to HBsAg-positive women are identified (on the basis of application of racial/ethnic-specific HBsAg prevalence estimates to U.S. natality data) for case management, which maximizes timely delivery of postexposure immunoprophylaxis (11; CDC, unpublished data, 2004). The need for proper management of women without prenatal care, including HBsAg testing at the time of admission for delivery and administration of the first dose of vaccine to infants <12 hours of birth, is underscored by the higher prevalence of HBsAg seropositivity among these women than among women who are screened prenatally (12). Even when maternal HBsAg testing does occur, certain infants of HBsAg-positive mothers do not receive postexposure immuno-

BOX 1. Immunization strategy to eliminate transmission of hepatitis B virus (HBV) infection in the United States

- Universal vaccination of infants beginning at birth
- Prevention of perinatal HBV infection through
  - routine screening of all pregnant women for hepatitis B surface antigen (HBsAg), and
  - immunoprophylaxis of infants born to HBsAg-positive women and infants born to women with unknown HBsAg status
- Routine vaccination of previously unvaccinated children and adolescents
- Vaccination of previously unvaccinated adults at increased risk for infection

prophylaxis because of testing errors and lapses in reporting of test results (13), and infants of women with unknown HBsAg status at the time of delivery often do not receive a birth dose of vaccine (14). Birth dose coverage in 2004 was only 46% (National Immunization Survey, unpublished data, 2004), and coverage has not returned to levels from before July 1999 (54%), when recommendations were made to temporarily suspend administration of hepatitis B vaccines at birth until vaccines that do not contain thimerosal as a preservative became available (15). Among adolescents, efforts to prevent HBV transmission are hampered by the low rate of healthcare visits in this age group compared with that of young children and the frequency of initiation of high-risk behaviors.

To address these remaining challenges and accelerate progress toward elimination of HBV transmission in the United States, the ACIP has updated the hepatitis B immunization recommendations for infants, children, and adolescents and supplemented the recommendations with strategies for implementation. The recommendations and implementation strategies address prevention of perinatal and early childhood transmission and routine vaccination of children and adolescents. A main focus is on universal infant vaccination beginning at birth, which provides a “safety net” for prevention of perinatal infection, prevents early childhood infections, facilitates implementation of universal vaccination recommendations, and prevents infections in adolescents and adults. The second part of the ACIP statement, which includes updated recommendations and implementation strategies to increase hepatitis B vaccination among unvaccinated adults, will be published separately (16).

**Major Updates to the Recommendations**

This report provides updated recommendations and approaches to address challenges in implementing the strategy to eliminate HBV transmission in the United States. These include the following measures:

- **Improve prevention of perinatal and early childhood HBV transmission.** Implement delivery hospital policies and procedures, case-management programs, and laws and regulations to improve identification of infants born to HBsAg-positive mothers and to mothers with unknown HBsAg status at the time of delivery, ensure administration of appropriate postexposure immunoprophylaxis to these infants beginning at birth, and administer a birth dose of hepatitis B vaccine to medically stable infants who weigh >2,000 g and who are born to HBsAg-negative mothers.

Hepatitis B: What Hospitals Need to Do to Protect Newborns www.immunize.org/protect-newborns
• Improve vaccine coverage of children and adolescents who were not previously vaccinated. Implement immunization record reviews for all children aged 11–12 years and children and adolescents aged <19 years who were born in countries in which HBV endemicity is high or intermediate (Figure 1 and Box 2); adopt hepatitis B vaccine requirements for school entry; and vaccinate all unvaccinated adolescents in settings that provide health-care services to persons in this age group.

**Background**

**Clinical Features and Natural History of HBV Infection**

HBV is a 42-nm DNA virus classified in the *Hepadnaviridae* family. The liver is the primary site of HBV replication. After a susceptible person is exposed, the virus enters the liver via the bloodstream; no evidence exists indicating that the virus replicates at mucosal surfaces. HBV infection can produce either asymptomatic or symptomatic infection. The average incubation period is 90 days (range: 60–150 days) from exposure to onset of jaundice and 60 days (range: 40–90 days) from exposure to onset of abnormal serum alanine aminotransferase (ALT) levels (17,18).

The onset of acute disease is usually insidious. Infants and young children (aged <10 years) are typically asymptomatic (19). When present, clinical symptoms and signs might include anorexia, malaise, nausea, vomiting, abdominal pain, and jaundice. Extrahepatic manifestations of disease (e.g., skin rashes, arthralgias, and arthritis) also can occur (20). The fatality rate among persons with reported acute hepatitis B is 0.5%–1.5%, with highest rates in adults aged >60 years (21).

Although the consequences of acute hepatitis B can be severe, the majority of serious sequelae associated with HBV disease occur in persons who are chronically infected. Persons with chronic infection also serve as the major reservoir for continued HBV transmission. Chronic infection occurs in approximately 90% of infected infants, 30% of infected children aged <5 years, and <5% of infected persons aged ≥5 years, with continuing viral replication in the liver and persistent viremia (19,22–24). Primary infections also become chronic more fre-
BOX 2. Geographic areas with intermediate* and high† hepatitis B virus endemicity

Africa: all countries
South Asia: all countries except Sri Lanka
Western Pacific: all countries and territories except Australia and New Zealand
Middle East: all countries except Cyprus
Eastern Europe: all countries except Hungary
Newly Independent States of the former Soviet Union: all countries
Western Europe: Greece, Italy, Malta, Portugal, and Spain
North America: Alaska Natives and indigenous populations of Northern Canada and Greenland
Central America: Belize, Guatemala, Honduras, and Panama
South America: Argentina, Bolivia, Brazil, Ecuador, Guyana, Suriname, Venezuela, and the Amazonian areas of Colombia and Peru
Caribbean: Antigua and Barbuda, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Puerto Rico, St. Kitts and Nevis, St. Lucia, St. Vincent and Grenadines, Trinidad and Tobago, and Turks and Caicos

*Hepatitis B surface antigen (HBsAg) prevalence of 2%–7%.
†HBsAg prevalence of ≥8%.

Interpretation of Serologic Markers of HBV Infection

The antigens and antibodies associated with HBV infection include HBsAg and antibody to HBsAg (anti-HBs), hepatitis B core antigen (HBCAg) and antibody to HBCAg (anti-HBc), and hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe). At least one serologic marker is present during the different phases of HBV infection (Table 1) (18,36). Serologic assays are commercially available for all markers except HBCAg because no free HBCAg circulates in blood.

The presence of a confirmed HBSAg result is indicative of ongoing HBV infection. All HBsAg-positive persons should be considered infectious. In newly infected persons, HBsAg is the only serologic marker detected during the first 3–5 weeks after infection, and it persists for variable periods at very low levels. The average time from exposure to detection of HBSAg is 30 days (range: 6–60 days) (17,18). Highly sensitive single-

<table>
<thead>
<tr>
<th>Serologic marker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
</tr>
<tr>
<td>anti-HBcanti-HBc</td>
</tr>
<tr>
<td>Anti-HBs</td>
</tr>
<tr>
<td>Interpretation</td>
</tr>
<tr>
<td>HBsAg*</td>
</tr>
<tr>
<td>--</td>
</tr>
<tr>
<td>+††§§</td>
</tr>
<tr>
<td>+ + +</td>
</tr>
<tr>
<td>--</td>
</tr>
<tr>
<td>+</td>
</tr>
<tr>
<td>--</td>
</tr>
<tr>
<td>--</td>
</tr>
</tbody>
</table>

*Hepatitis B surface antigen.
†Antibody to hepatitis B core antigen.
§Immunoglobulin M.
¶Antibody to HBsAg.
**Negative test result.
††Positive test result.
§§To ensure that an HBsAg-positive test result is not a false positive, samples with repeatedly reactive HBsAg results should be tested with a licensed (and, if appropriate, neutralizing confirmatory) test.
¶¶Persons positive for only anti-HBc are unlikely to be infectious except under circumstances in which they are the source for direct percutaneous exposure of susceptible recipients to large quantities of virus (e.g., blood transfusion or organ transplant).
†††Milli-International Units per milliliter.
sample nucleic acid tests can detect HBV DNA in the serum of an infected person 10–20 days before detection of HBsAg (37). Transient HBsAg positivity has been reported for up to 18 days after vaccination and is clinically insignificant (38,39).

Anti-HBc appears at the onset of symptoms or liver test abnormalities in acute HBV infection and persists for life. Acute or recently acquired infection can be distinguished by the presence of the IgM class of anti-HBc, which is detected at the onset of acute hepatitis B and persists for up to 6 months if the disease resolves. In patients who develop chronic hepatitis B, IgM anti-HBc can persist at low levels during viral replication and can result in positive tests for IgM anti-HBc (40). In addition, false-positive IgM anti-HBc test results can occur. Because the positive predictive value is low in asymptomatic persons, for diagnosis of acute hepatitis B, testing for IgM anti-HBc should be limited to persons with clinical evidence of acute hepatitis or an epidemiologic link to a case.

In persons who recover from HBV infection, HBsAg is eliminated from the blood, usually within 3–4 months, and anti-HBs develops during convalescence. The presence of anti-HBs typically indicates immunity from HBV infection. Infection or immunization with one genotype of HBV confers immunity to all genotypes. In addition, anti-HBs can be detected for several months after hepatitis B immune globulin (HBIG) administration. The majority of persons who recover from natural infection will be positive for both anti-HBs and anti-HBc, whereas persons who respond to hepatitis B vaccine have only anti-HBs. In persons who become chronically infected, HBsAg and anti-HBc persist, typically for life. HBsAg will become undetectable in approximately 0.5%–2% of chronically infected persons yearly, and anti-HBs will occur in the majority of these persons (41–44).

In certain persons, the only HBV serologic marker detected in serum is anti-HBc. Isolated anti-HBc can occur after HBV infection among persons who have recovered but whose anti-HBs levels have waned or among persons in whom anti-HBs failed to occur. Persons in the latter category include those with circulating HBsAg levels not detectable by commercial assays. These persons are unlikely to be infectious except under circumstances in which they are the source for direct percutaneous exposure of susceptible recipients to substantial quantities of virus (e.g., through blood transfusion or following liver transplantation) (45). HBV DNA has been detected in the blood of <5% of persons with isolated anti-HBc (46). Typically, the frequency of isolated anti-HBc relates directly to the prevalence of HBV infection in the population. In populations with a high prevalence of HBV infection, isolated anti-HBc likely indicates previous infection, with loss of anti-HBs. For persons in populations with a low prevalence of HBV infection, an isolated anti-HBc result often represents a false-positive reaction. The majority of these persons have a primary anti-HBs response after a 3-dose series of hepatitis B vaccine (47,48). Infants who are born to HBsAg-positive mothers and who do not become infected might have detectable anti-HBc for ≤24 months after birth from passively transferred maternal antibody.

HBsAg can be detected in the serum of persons with acute or chronic HBV infection. The presence of HBeAg correlates with viral replication and high levels of virus (i.e., high infectivity) (49,50). Anti-HBc correlates with the loss of replicating virus and with lower levels of virus, although reversion to HBeAg positivity has been observed (44).

Epidemiology of HBV Infection

Transmission

HBV is transmitted by percutaneous (i.e., puncture through the skin) or mucosal (i.e., direct contact with mucous membranes) exposure to infectious blood or to body fluids that contain blood. All HBsAg-positive persons are infectious, but those who are also HBeAg positive are more infectious because their blood contains high titers of HBV (typically 107–109 virions/mL) (49,50). Although HBsAg has been detected in multiple body fluids, only serum, semen, and saliva have been demonstrated to be infectious (51,52). HBV is comparatively stable in the environment and remains viable for ≥7 days on environmental surfaces at room temperature (53). HBV at concentrations of 102–3 virions/mL can be present on environmental surfaces in the absence of any visible blood and still cause transmission (53,54).

For infants and children, the two primary sources of HBV infection are perinatal transmission from infected mothers and horizontal transmission from infected household contacts. Adolescents are at risk for HBV infection primarily through high-risk sexual activity (i.e., sex with more than one partner and male sexual activity with other males) and injection-drug use (21). Transmission of HBV via transfusion of blood and plasma-derived products is rare because of donor screening for HBsAg and viral inactivation procedures.

For a newborn infant whose mother is positive for both HBsAg and HBeAg, the risk for chronic HBV infection is 70%–90% by age 6 months in the absence of postexposure immunoprophylaxis (55–57). For infants of women who are HBsAg positive but HBeAg negative, the risk for chronic infection is <10% in the absence of postexposure immunoprophylaxis (58–60). Rare cases of fulminant hepatitis B among perinatally infected infants also have been reported (61,62). Studies suggest that breastfeeding by an HBsAg-
positive mother does not increase the risk for acquisition of HBV infection in the infant (63).

Children who are not infected at birth remain at risk from long-term interpersonal contact with their infected mothers. In one study, 38% of infants who were born to HBsAg-positive mothers and who were not infected perinatally became infected by age 4 years (64). In addition, children living with any chronically infected persons are at risk for becoming infected through percutaneous or mucosal exposures to blood or infectious body fluids (e.g., sharing a toothbrush, contact with exudates from dermatologic lesions, contact with HBsAg-contaminated surfaces). HBV transmission rates to susceptible household contacts of chronically infected persons have varied (range: 14%–60%) (65,66). High rates of infection also have been reported among unvaccinated long-term residents of institutions for the mentally handicapped (67,68), and, in rare instances, person-to-person transmission has been reported in child care settings (69,70).

Incidence

During 1990–2004, overall incidence of reported acute hepatitis B declined 75%, from 8.5 to 2.1 per 100,000 population. The most dramatic declines occurred in the cohort of children to whom recommendations for routine infant and adolescent vaccination have applied. Incidence among children aged <12 years and adolescents aged 12–19 years declined 94%, from 1.1 to 0.36 and 6.1 to 2.8 per 100,000 population, respectively (Figure 2). Since implementation of routine childhood immunization, an estimated 6,800 perinatal infections and an additional 18,700 infections during the first 10 years of life have been prevented annually in the United States (71).

Although infections in infants and children aged <10 years represented <10% of all HBV infections before implementation of childhood immunization programs, childhood infections resulted in an estimated 30%–40% of the chronic HBV infections among persons who acquired their infections in the United States (7). In two population-based studies conducted among Asian/Pacific Islander children who were born in the United States before perinatal hepatitis B prevention programs were widely implemented, 61%–66% of the chronic HBV infections occurred in children born to HBsAg-negative mothers (72,73). A substantial proportion of these chronic infections would not have been prevented by a selective program of identification and immunization of only infants born to HBsAg-positive mothers.

In addition to declines in incidence among all age groups, racial disparities in hepatitis B incidence among children have been substantially reduced (Figure 3). The reduction of the disparity between Asian/Pacific Islander and other children is consistent with recent observations noting a decline in seroprevalence of HBV infection after successful implementation of routine hepatitis B vaccination among Asians who have recently immigrated to the United States (74,75). However, as hepatitis B incidence has declined among U.S.-born children, unvaccinated foreign-born children account for a high proportion of infections. During 2001–2002, of 19 children born after 1991 in whom acute hepatitis B had been verified, eight (42%) were foreign born (76).

Prevalence

In the U.S. population, the overall age-adjusted prevalence of HBV infection (including persons with chronic infection and those with previous infection) was 4.9% in the third...
National Health and Nutrition Examination Survey (NHANES III, 1988–1994) (77). Foreign-born persons (particularly Asian/Pacific Islanders) who have emigrated from countries in which HBV is endemic (Figure 1 and Box 2) contribute disproportionately to the burden of chronic HBV infection in the United States. The prevalence of chronic HBV infection among foreign-born persons immigrating to the United States from Central and Southeast Asia, the Middle East, and Africa varies (range: 5%–15%) and reflects the patterns of HBV infection in the countries and regions of origin for these persons. During 1994–2003, approximately 40,000 immigrants with chronic HBV infection were admitted annually to the United States for permanent residence (78; CDC, unpublished data, 2005).

Prophylaxis Against HBV Infection

Hepatitis B Vaccine

HBsAg is the antigen used for hepatitis B vaccination (79,80). Vaccine antigen can be purified from the plasma of persons with chronic HBV infection or produced by recombinant DNA technology. Vaccines available in the United States use recombinant DNA technology to express HBsAg in yeast, which is then purified from the cells by biochemical and biophysical separation techniques (81,82). Hepatitis B vaccines licensed in the United States are formulated to contain 10–40 µg of HBsAg protein/mL. Since March 2000, hepatitis B vaccines produced for distribution in the United States do not contain thimerosal as a preservative or contain only a trace amount (<1.0 mcg mercury/mL) from the manufacturing process (83,84). Hepatitis B vaccine is available as a single-antigen formulation and also in fixed combination with other vaccines. Two single-antigen vaccines are available in the United States: Recombivax HB® (Merck & Co., Inc., Whitehouse Station, New Jersey) and Engerix-B® (GlaxoSmithKline Biologicals, Rixensart, Belgium). Of the three licensed combination vaccines, one (Twinrix® [GlaxoSmithKline Biologicals, Rixensart, Belgium]) is used for vaccination of adults, and two (Comvax® [Merck & Co., Inc., Whitehouse Station, New Jersey] and Pediarix® [GlaxoSmithKline Biologicals, Rixensart, Belgium]) are used for vaccination of infants and young children. Twinrix contains recombinant HBsAg and inactivated hepatitis A virus. Comvax contains recombinant HBsAg and Haemophilus influenzae type b (Hib) polysaccharide conjugated to Nisseria meningitidis outer membrane protein complex. Pediarix contains recombinant HBsAg, diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), and inactivated poliovirus (IPV).

HBIG

HBIG provides passively acquired anti-HBs and temporary protection (i.e., 3–6 months) when administered in standard doses. HBIG is typically used as an adjunct to hepatitis B vaccine for postexposure immunoprophylaxis to prevent HBV infection. HBIG administered alone is the primary means of protection after an HBV exposure for nonresponders to hepatitis B vaccination.

HBIG is prepared from the plasma of donors with high concentrations of anti-HBs. The plasma is screened to eliminate donors who are positive for HBsAg, antibodies to HIV and hepatitis C virus (HCV), and HCV RNA. In addition, proper manufacturing techniques for HBIG inactivate viruses (e.g., HBV, HCV, and HIV) from the final product (85,86). No evidence exists that HBV, HCV, or HIV ever has been transmitted by HBIG commercially available in the United States. HBIG that is commercially available in the United States does not contain thimerosal.

Vaccination Schedules and Results of Vaccination

Preexposure Vaccination

Infants and Children

Primary vaccination consists of ≥3 intramuscular doses of hepatitis B vaccine (Table 2). Vaccine schedules for infants and children (Tables 3–5) are determined on the basis of immunogenicity data and the need to integrate hepatitis B vaccine into a harmonized childhood vaccination schedule. Although not all possible schedules for each product have been evaluated in clinical trials, available licensed formulations for both single-antigen vaccines produce high (>95%) levels of seroprotection among infants and children when administered in multiple schedules (87–91).

The immunogenicity of the combined hepatitis B–Hib conjugate vaccine (Comvax) and the combined hepatitis B–DTaP–IPV vaccine (Pediarix) is equivalent to that of their individual antigens administered separately. However, these vaccines cannot be administered to infants aged <6 weeks; only single-antigen hepatitis B vaccine may be used for the birth dose. Use of 4-dose hepatitis B vaccine schedules, including schedules with a birth dose, has not increased vaccine reactogenicity (92,93). Anti-HBs responses after a 3-dose series of hepatitis B-containing combination vaccines among infants who were previously vaccinated at birth with single-antigen hepatitis B vaccine are comparable to those observed after a 3-dose series of combination vaccine without a birth dose (93).
TABLE 2. Recommended doses of currently licensed formulations of hepatitis B vaccine, by age group and vaccine type

<table>
<thead>
<tr>
<th>Age group</th>
<th>Single-antigen vaccine</th>
<th>Combination vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Recombivax HB</td>
<td>Engerix-B</td>
</tr>
<tr>
<td></td>
<td>Dose (µg)  Volume (mL)</td>
<td>Dose (µg)  Volume (mL)</td>
</tr>
<tr>
<td>Infants (&lt;1 yr)</td>
<td>5 0.5 10 0.5</td>
<td>5 0.5 10 0.5</td>
</tr>
<tr>
<td>Children (1–10 yrs)</td>
<td>5 0.5 10 0.5</td>
<td>NA NA NA NA NA NA NA</td>
</tr>
<tr>
<td>Adolescents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11–15 yrs</td>
<td>10†† 1.0 NA NA NA</td>
<td>NA NA NA NA NA NA NA</td>
</tr>
<tr>
<td>11–19 yrs</td>
<td>5 0.5 10 0.5</td>
<td>NA NA NA NA NA NA NA</td>
</tr>
<tr>
<td>Adults (≥20 yrs)</td>
<td>10 1.0 20 1.0</td>
<td>NA NA NA NA NA NA NA</td>
</tr>
<tr>
<td>Hemodialysis patients and other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>immunocompromised persons</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20 yrs§§</td>
<td>5 0.5 10 0.5</td>
<td>NA NA NA NA NA NA NA</td>
</tr>
<tr>
<td>≥20 yrs</td>
<td>40††† 1.0 40*** 2.0</td>
<td>NA NA NA NA NA NA NA</td>
</tr>
</tbody>
</table>

* Combined hepatitis B–Haemophilus influenzae type b conjugate vaccine. This vaccine cannot be administered at birth, before age 6 weeks, or after age 71 months.
† Combined hepatitis B–diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine. This vaccine cannot be administered at birth, before age 6 weeks, or at age ≥7 years.
‡ Combined hepatitis A and hepatitis B vaccine. This vaccine is recommended for persons aged ≥18 years who are at increased risk for both hepatitis B virus and hepatitis A virus infections.
¶ Recombinant hepatitis B surface antigen protein dose.
** Not applicable.
†† Adult formulation administered on a 2-dose schedule.
§§ Higher doses might be more immunogenic, but no specific recommendations have been made.
¶¶ Dialysis formulation administered on a 3-dose schedule at age 0, 1, and 6 months.
*** Two 1.0-mL doses administered at one site, on a 4-dose schedule at age 0, 1, 2, and 6 months.

Birth Dose

Hepatitis B vaccine can be administered soon after birth with only minimal decrease in immunogenicity, compared with administration at older ages, and no decrease in protective efficacy (87). Administration of a birth dose of hepatitis B vaccine is required for effective postexposure immunoprophylaxis to prevent perinatal HBV infection. Although infants who require postexposure immunoprophylaxis should be identified by maternal HBsAg testing, administering a birth dose to infants even without HBIG serves as a “safety net” to prevent perinatal infection among infants born to HBsAg-positive mothers who are not identified because of errors in maternal HBsAg testing or failures in reporting of test results (13). The birth dose also provides early protection to infants at risk for infection after the perinatal period. Administration of a birth dose has been associated with higher rates of on-time completion of the hepatitis B vaccine series (15,94). In certain populations, the birth dose has been associated with improved completion rates for all other infant vaccines (95), although findings have not been consistent (15,94).

Adolescents

Recommended vaccination schedules for adolescents balance available immunogenicity data with the need to achieve compliance with vaccination in this age group (Tables 2 and 5). Both licensed single-antigen hepatitis B vaccines administered intramuscularly at 0, 1, and 6 months produce a >95% sero-protection rate in adolescents. Equivalent seroprotection rates are achieved among adolescents vaccinated at 0, 1–2, and 4 months and 0, 12, and 24 months. The adult (10 µg) dose of Recombivax-HB administered in a 2-dose schedule to children and adolescents aged 11–15 years at 0 and 4–6 months produces antibody levels equivalent to those obtained with the 5-µg dose administered on a 3-dose schedule (96,97). However, no data on long-term antibody persistence or protection are available for 2-dose schedules. No combination vaccines containing hepatitis B vaccine antigen are approved for use in adolescents aged 11–17 years.

Nonstandard Vaccine Schedules

No apparent effect on immunogenicity has been documented when minimum spacing of doses is not achieved precisely. Increasing the interval between the first 2 doses has little effect on immunogenicity or final antibody concentration (98–100). The third dose confers the maximum level of seroprotection but acts primarily as a booster and appears to provide optimal long-term protection (101). Longer intervals between the last 2 doses result in higher final antibody levels but might increase the risk for acquisition of HBV infection among persons who have a delayed response to vaccination. No differences in immunogenicity have been observed when 1 or 2 doses of hepatitis B vaccine produced by one manufacturer are followed by doses from a different manufacturer (102).
TABLE 3. Hepatitis B vaccine schedules for newborn infants, by maternal hepatitis B surface antigen (HBsAg) status

<table>
<thead>
<tr>
<th>Maternal HBsAg status</th>
<th>Single-antigen vaccine</th>
<th>Single antigen + combination vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive HBsAg†</td>
<td>1† Birth (&lt;12 hrs)</td>
<td>1† Birth (&lt;12 hrs)</td>
</tr>
<tr>
<td>Positive HBsAg‡</td>
<td>2 1–2 mos</td>
<td>2 2 mos</td>
</tr>
<tr>
<td>Positive</td>
<td>3 6 mos</td>
<td>3 4 mos</td>
</tr>
<tr>
<td>Positive</td>
<td>4† 6 mos (Pediarix)</td>
<td>4† 6 mos (Pediarix) or 12–15 mos (Comvax)</td>
</tr>
<tr>
<td>Unknown**</td>
<td>1† Birth (&lt;12 hrs)</td>
<td>1† Birth (&lt;12 hrs)</td>
</tr>
<tr>
<td></td>
<td>2 1–2 mos</td>
<td>2 2 mos</td>
</tr>
<tr>
<td></td>
<td>3 6 mos</td>
<td>3 4 mos</td>
</tr>
<tr>
<td></td>
<td>4† 6 mos (Pediarix)</td>
<td>4† 6 mos (Pediarix) or 12–15 mos (Comvax)</td>
</tr>
<tr>
<td>Negative</td>
<td>1† Birth (before discharge)</td>
<td>1† Birth (before discharge)</td>
</tr>
<tr>
<td></td>
<td>2 1–2 mos</td>
<td>2 2 mos</td>
</tr>
<tr>
<td></td>
<td>3 6–18 mos</td>
<td>3 4 mos</td>
</tr>
<tr>
<td></td>
<td>4† 6 mos (Pediarix)</td>
<td>4† 6 mos (Pediarix) or 12–15 mos (Comvax)</td>
</tr>
</tbody>
</table>

* See Table 4 for vaccine schedules for preterm infants weighing <2,000 g.
† Recombivax HB or Engerix-B should be used for the birth dose. Comvax and Pediarix cannot be administered at birth or before age 6 weeks.
‡ Hepatitis B immune globulin (0.5 mL) administered intramuscularly in a separate site from vaccine.
§ The final dose in the vaccine series should not be administered before age 24 weeks (164 days).
** Mothers should have blood drawn and tested for HBsAg as soon as possible after admission for delivery; if the mother is found to be HBsAg positive, the infant should receive HBIG as soon as possible but no later than age 7 days.
†† On a case-by-case basis and only in rare circumstances, the first dose may be delayed until after hospital discharge for an infant who weighs ≥2,000 g and whose mother is HBsAg negative, but only if a physician’s order to withhold the birth dose and a copy of the mother’s original HBsAg-negative laboratory report are documented in the infant’s medical record.

TABLE 4
Hepatitis B Immunization Management of Preterm Infants Weighing <2,000 g, by Maternal Hepatitis B Surface Antigen (HBsAg) Status

<table>
<thead>
<tr>
<th>Maternal HBsAg status</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>• Administer HBIG* + single-antigen hepatitis B vaccine within 12 hrs of birth.</td>
</tr>
<tr>
<td></td>
<td>• Do not count the birth dose as part of the vaccine series.</td>
</tr>
<tr>
<td></td>
<td>• Administer 3 additional hepatitis B vaccine doses with</td>
</tr>
<tr>
<td></td>
<td>- single-antigen vaccine at ages 1, 2, 3, and 6 mos, or</td>
</tr>
<tr>
<td></td>
<td>- hepatitis B-containing combination vaccine at ages 2, 4, and 6 mos (Pediarix) or 2, 4, and 12–15 mos (Comvax).†</td>
</tr>
<tr>
<td></td>
<td>• Test for HBsAg and antibody to HBsAg 1–2 mos after completion of ≥3 doses of a licensed hepatitis B vaccine series (i.e., at age 9–18 mos, generally at the next well-child visit). Testing should not be performed before age 9 mos nor within 4 wks of the most recent vaccine dose.</td>
</tr>
<tr>
<td>Unknown</td>
<td>• Administer HBIG* + single-antigen hepatitis B vaccine within 12 hrs of birth.</td>
</tr>
<tr>
<td></td>
<td>• Test mother for HBsAg.</td>
</tr>
<tr>
<td></td>
<td>• Do not count the birth dose as part of the vaccine series.</td>
</tr>
<tr>
<td></td>
<td>• Administer 3 additional hepatitis B vaccine doses with</td>
</tr>
<tr>
<td></td>
<td>- single-antigen vaccine at ages 1, 2, 3, and 6 mos, or</td>
</tr>
<tr>
<td></td>
<td>- hepatitis B-containing combination vaccine at ages 2, 4, and 6 mos (Pediarix) or 2, 4, and 12–15 mos (Comvax).†</td>
</tr>
<tr>
<td>Negative</td>
<td>• Delay first dose of hepatitis B vaccine until age 1 mo or hospital discharge.</td>
</tr>
<tr>
<td></td>
<td>• Complete the hepatitis B vaccine series with</td>
</tr>
<tr>
<td></td>
<td>- single-antigen vaccine at ages 2 mos and 6–18 mos, or</td>
</tr>
<tr>
<td></td>
<td>- hepatitis B-containing combination vaccine at ages 2, 4, and 6 mos (Pediarix) or 2, 4, and 12–15 mos (Comvax).†</td>
</tr>
</tbody>
</table>

* Hepatitis B immune globulin.
† The final dose in the vaccine series should not be administered before age 24 weeks (164 days).

Response to Revaccination
A study of infants born to HBsAg-positive mothers who did not respond to a primary vaccine series indicated that all those not infected with HBV responded satisfactorily to a repeat 3-dose revaccination series (103). No data suggest that children who have no detectable antibody after 6 doses of vaccine would benefit from additional doses.

Groups Requiring Different Vaccination Doses or Schedules

Preterm infants. Preterm infants weighing <2,000 g at birth have a decreased response to hepatitis B vaccine administered before age 1 month (104–106). By age 1 month, medically stable preterm infants, regardless of initial birth weight or gestational age, have a response to vaccination that is comparable to that of full-term infants (107–110).

Hemodialysis patients and other immunocompromised persons. Although data concerning the response of pediatric hemodialysis patients to vaccination with standard pediatric doses are lacking, protective levels of antibody occur in 75%–97% of those who receive higher dosages (20 µg) on either the 3- or the 4-dose schedule (111–114). Humoral response to hepatitis B vaccination is also reduced in other children and adolescents who are immunocompromised (e.g., hematopoietic stem cell transplant recipients, patients undergoing chemotherapy, and HIV-infected persons) (115–119). Modified dosing regimens, including a doubling of the standard antigen dose or administration of additional doses, might increase response rates (120). However, data on response to these alternative vaccination schedules are limited (121).

Immune Memory
Anti-HBs is the only easily measurable correlate of vaccine-induced protection. Immunocompetent persons who achieve anti-HBs concentrations ≥10 mIU/mL after preexposure vaccination have virtually complete protection against both acute disease and chronic infection even if anti HBs concentrations subsequently decline to <10 mIU/mL (122–125). Although immunogenicity is lower among immunocompromised persons, those who achieve and maintain a protective antibody response before exposure to HBV have a high level of protection from infection.

After primary immunization with hepatitis B vaccine, anti-HBs concentrations decline rapidly within the first
TABLE 5. Hepatitis B vaccine schedules for children, adolescents, and adults*

<table>
<thead>
<tr>
<th>Age</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children (1–10 yrs)</td>
<td>0, 1, and 6 mos†</td>
</tr>
<tr>
<td></td>
<td>0, 2, and 4 mos†</td>
</tr>
<tr>
<td></td>
<td>0, 1, 2, and 12 mos†</td>
</tr>
<tr>
<td>Adolescents (11–19 yrs)</td>
<td>0, 1, and 6 mos†</td>
</tr>
<tr>
<td></td>
<td>0, 1, and 4 mos†</td>
</tr>
<tr>
<td></td>
<td>0, 2, and 4 mos†</td>
</tr>
<tr>
<td></td>
<td>0, 12, and 24 mos†</td>
</tr>
<tr>
<td></td>
<td>0 and 4–6 mos††</td>
</tr>
<tr>
<td></td>
<td>0, 1, 2, and 12 mos†</td>
</tr>
<tr>
<td>Adults (≥20 yrs)</td>
<td>0, 1, and 6 mos††</td>
</tr>
<tr>
<td></td>
<td>0, 1, and 4 mos††</td>
</tr>
<tr>
<td></td>
<td>0, 2, and 4 mos††</td>
</tr>
<tr>
<td></td>
<td>0, 1, 2, and 12 mos††</td>
</tr>
</tbody>
</table>

* Children, adolescents, and adults may be vaccinated according to any of the schedules indicated, except as noted. Selection of a schedule should consider the need to optimize compliance with vaccination
† Pediatric/adolescent formulation.
‡ A 2-dose schedule of Recombivax-HB adult formulation (10 µg) is licensed for adolescents aged 11–15 years. When scheduled to receive the second dose, adolescents aged >15 years should be switched to a 3-dose series, with doses 2 and 3 consisting of the pediatric formulation administered on an appropriate schedule.
§ A 4-dose schedule of Engerix B is licensed for all age groups.
** Adult formulation.
†† Twinrix may be administered to persons aged ≥18 years at 0, 1, and 6 months.

year and more slowly thereafter. Among children who respond to a primary vaccine series with antibody levels ≥10 mIU/mL, 15%–50% have low or undetectable concentrations of anti-HBs (anti-HBs loss) 5–15 years after vaccination (126–130). The persistence of detectable anti-HBs after vaccination, in the absence of exposure to HBV, depends on the level of post-vaccination antibody concentration.

Despite declines in anti-HBs to <10 mIU/mL, nearly all vaccinated persons are still protected against HBV infection. The mechanism for continued vaccine-induced protection is thought to be the preservation of immune memory through selective expansion and differentiation of clones of antigen-specific B and T lymphocytes (131). Persistence of vaccine-induced immune memory among persons who responded to a primary childhood vaccine series 13–23 years earlier but then had levels of anti-HBs below 10 mIU/mL has been demonstrated by an anamnestic increase in anti-HBs levels in 67%–76% of these persons 2–4 weeks after administration of an additional vaccine dose (132,133). Although direct measurement of immune memory is not yet possible, these data indicate that a high proportion of vaccine recipients retain immune memory and would develop an anti-HBs response upon exposure to HBV.

Studies of cohorts of immunocompetent persons vaccinated as children or infants also indicate that, despite anti-HBs loss years after immunization, nearly all vaccinated persons who respond to a primary series remain protected from HBV infection. No clinical cases of hepatitis B have been observed in follow-up studies conducted 15–20 years after vaccination among immunocompetent vaccinated persons with antibody levels ≥10 mIU/mL. Certain studies have documented breakthrough infections (detected by the presence of anti-HBc or HBV DNA) in a limited percentage of vaccinated persons (130,131), but these infections are usually transient and asymptomatic; chronic infections have been documented only rarely (134). Breakthrough infections resulting in chronic infection have been observed only among vaccinated infants born to HBsAg-positive women.

Limited data are available on the duration of immune memory after hepatitis B vaccination in immunocompromised persons (e.g., HIV-infected patients, dialysis patients, patients undergoing chemotherapy, or hematopoietic stem cell transplant patients). No clinically important HBV infections have been documented among immunocompromised persons who maintain protective levels of anti-HBs. In studies of long-term protection among HIV-infected persons, breakthrough infections occurring after a decline in anti-HBs concentrations to <10 mIU/mL have been transient and asymptomatic (135). However, among hemodialysis patients who respond to the vaccine, clinically significant HBV infection has been documented in persons who have not maintained anti-HBs concentrations of ≥10 mIU/mL (136).

Postexposure Prophylaxis

Both passive-active postexposure prophylaxis (PEP) with HBIG and hepatitis B vaccine and active PEP with hepatitis B vaccine alone have been demonstrated to be highly effective in preventing transmission after exposure to HBV (137–140). HBIG alone has also been demonstrated to be effective in preventing HBV transmission (141–144), but with the availability of hepatitis B vaccine, HBIG typically is used as an adjunct to vaccination.

The major determinant of the effectiveness of PEP is early administration of the initial dose of vaccine. The effectiveness of PEP diminishes the longer it is initiated after exposure (17,145,146). Studies are limited on the maximum interval after exposure during which PEP is effective, but the interval is unlikely to exceed 7 days for perinatal (147) and needlestick (140–142) exposures and 14 days for sexual exposures (122,138,139,143,144).

No data are available on the efficacy of HBsAg-containing combination vaccines when used to complete the vaccine series for PEP, but the efficacy of combination vaccines is expected to be similar to that of single-antigen vaccines because the HBsAg component induces a comparable anti-HBs response.
Perinatal HBV Exposure

Passive-active PEP. PEP with hepatitis B vaccine and HBIG administered 12–24 hours after birth, followed by completion of a 3-dose vaccine series, has been demonstrated to be 85%–95% effective in preventing acute and chronic HBV infection in infants born to women who are positive for both HBsAg and HBeAg (137). Although clinical trials have evaluated the efficacy of passive-active PEP with hepatitis B vaccine and HBIG administered only within 24 hours of birth, studies of passive immunoprophylaxis have demonstrated that HBIG provided protection when administered as late as 72 hours after exposure. The majority of clinical trials have evaluated the efficacy of passive-active PEP when the second vaccine dose was administered at age 1 month (137). Administration of HBIG plus vaccine at birth, 1 month, and 6 months and at birth, 2 months, and 6 months has demonstrated comparable efficacy in prevention of acute and chronic infection among infants born to women who were both HBsAg and HBeAg positive (Cladd E. Stevens, MD, New York Blood Center, personal communication, 1994).

Infants born to HBsAg-positive/HBeAg-negative mothers who receive passive-active PEP with HBIG and hepatitis B vaccine should have the same high degree of protection as infants born to women who are HBsAg positive/HBeAg positive. However, the efficacy of this regimen has not been examined in controlled clinical trials because the low infection rate would require an unattainable sample size.

Active PEP. Active PEP with hepatitis B vaccine alone (i.e., without HBIG) is frequently used in certain remote areas (e.g., Alaska and the Pacific Islands) where implementation of maternal HBsAg testing is difficult because no access exists to a laboratory. In randomized, placebo-controlled clinical trials, administration of hepatitis B vaccine in a 3- or 4-dose schedule without HBIG beginning ≤12 hours after birth has been demonstrated to prevent 70%–95% of perinatal HBV infections among infants born to women who are positive for both HBsAg and HBeAg (58,148–152). Population-based studies in areas with a high endemicity of HBV infection have demonstrated that active postexposure vaccination is highly effective in preventing infection when the first dose is administered soon after birth, the second at age 1–2 months, and the third at age 6–8 months (153–155).

Vaccine Safety

Hepatitis B vaccines have been demonstrated to be safe when administered to infants, children, adolescents, and adults. Since 1982, an estimated >60 million adolescents and adults and >40 million infants and children have been vaccinated in the United States.

Vaccine Reactogenicity

The most frequently reported side effects among persons receiving hepatitis B vaccine are pain at the injection site (3%–29%) and fever >99.9°F (>37.7°C) (1%–6%) (156,157). However, in placebo-controlled studies, these side effects were reported no more frequently among persons receiving hepatitis B vaccine than among persons receiving placebo (87). Administration of hepatitis B vaccine soon after birth has not been associated with an increased rate of elevated temperatures or microbiologic evaluations for possible sepsis in the first 21 days of life (158).

Adverse Events

A causal association has been established between receipt of hepatitis B vaccine and anaphylaxis (159). On the basis of data from the Vaccine Safety Datalink (VSD) project, the estimated incidence of anaphylaxis among children and adolescents who received hepatitis B vaccine is one case per 1.1 million vaccine doses distributed (95% confidence interval = 0.1–3.9) (160).

Early postlicensure surveillance of adverse events suggested a possible association between Guillain-Barré syndrome and receipt of the first dose of plasma-derived hepatitis B vaccine among U.S. adults (161). However, in a subsequent analysis of Guillain-Barré syndrome cases reported to CDC, FDA, and vaccine manufacturers, among an estimated 2.5 million adults who received ≥1 dose of recombinant hepatitis B vaccine during 1986–1990, the rate of Guillain-Barré syndrome occurring after hepatitis B vaccination did not exceed the background rate among unvaccinated persons (CDC, unpublished data, 1992). A review by persons with clinical expertise concluded that evidence was insufficient to reject or accept a causal association between Guillain-Barré syndrome and hepatitis B vaccination (159,162).

Multiple sclerosis (MS) has not been reported after hepatitis B vaccination among children. However, one retrospective case-control study (163,164) reported an association between hepatitis B vaccine and MS among adults. Multiple other studies (165–168) have demonstrated no association between hepatitis B vaccine and MS. Reviews of these data by panels of persons with clinical expertise have favored rejection of a causal association between hepatitis B vaccination and MS (169,170).

Chronic illnesses that have been reported in rare instances after hepatitis B vaccination include chronic fatigue syndrome (171), neurologic disorders (e.g., leukoencephalitis, optic neu-
ritis, and transverse myelitis) (172–174), rheumatoid arthritis (175,176), type 1 diabetes (177), and autoimmune disease (178). No evidence of a causal association between these conditions or other chronic illnesses and hepatitis B vaccine has been demonstrated (159,169,170,179–182).

Reported episodes of alopecia (hair loss) after rechallenge with hepatitis B vaccine suggest that vaccination might, in rare cases, trigger episodes of alopecia (183). However, a population-based study determined no statistically significant association between alopecia and hepatitis B vaccine (184).

No evidence exists of a causal association between hepatitis B vaccination, including administration of the birth dose, and sudden infant death syndrome (SIDS) or other causes of death during the first year of life (185–187). Infant death rates, including rates of SIDS, declined substantially in the United States during the 1990s, coincident with an increase in infant hepatitis B vaccination coverage from <1% to >90% and implementation of efforts to reduce SIDS through infant sleep positioning and separation from other persons in bed (188).

The safety of hepatitis B vaccine and other vaccines is assessed continuously through ongoing monitoring of data from VSD, the Vaccine Adverse Events Reporting System (VAERS), and other surveillance systems. Any adverse events after vaccination should be reported to VAERS; report forms and assistance are available from CDC at telephone 1-800-822-7967 or at http://www.vaers.hhs.gov.

**Contraindications and Precautions**

Hepatitis B vaccination is contraindicated for persons with a history of hypersensitivity to yeast or to any vaccine component (92,189–191). Despite a theoretic risk for allergic reaction to vaccination in persons with allergy to Saccharomyces cerevisiae (baker’s yeast), no evidence exists that documents adverse reactions after vaccination of persons with a history of yeast allergy.

Persons with a history of serious adverse events (e.g., anaphylaxis) after receipt of hepatitis B vaccine should not receive additional doses. As with other vaccines, vaccination of persons with moderate or severe acute illness, with or without fever, should be deferred until the illness resolves (192). Vaccination is not contraindicated in persons with a history of MS, Guillain-Barré syndrome, autoimmune disease (e.g., systemic lupus erythematosus or rheumatoid arthritis), or other chronic diseases.

Pregnancy is not a contraindication to vaccination. Limited data indicate no apparent risk for adverse events to developing fetuses when hepatitis B vaccine is administered to pregnant women (193). Current vaccines contain noninfectious HBsAg and should cause no risk to the fetus.

**Future Considerations**

Implementation of the recommendations and strategies in this document should ultimately lead to the elimination of HBV transmission in the United States. New information will have implications for this effort, and adjustments and changes are expected to occur.

**Long-Term Protection and Booster Doses**

Studies are needed to assess long-term protection after vaccination and the possible need for booster doses of vaccine. The longest follow-up studies of vaccine protection have been conducted in populations with an initially high endemicity of HBV infection (i.e., ≥8% prevalence of chronic infection) (130).

Implementation of hepatitis B vaccination programs in populations with a high endemicity of HBV infection has resulted in virtual elimination of new HBV infections by providing vaccine-induced immunity to susceptible persons. In these populations, ongoing exposure of vaccinated persons to persons with chronic HBV infection might complicate future efforts to assess long-term hepatitis B vaccine efficacy. Assessment of efficacy provided by hepatitis B immunization after 15–20 years will require studies among populations that continue to have exposures to HBsAg-positive persons (e.g., communities of immigrants from highly endemic countries, populations of injection-drug users, or health-care workers) and studies among populations with a low prevalence of infection.

**Immunization Escape Mutants**

Mutations in the S gene of HBV can lead to conformational changes in the a determinant of the HBsAg protein, which is the major target for neutralizing anti-HBs. These variants have been detected in humans infected with HBV, and concern has been expressed that these variants might replicate in the presence of vaccine-induced anti-HBs or anti-HBs contained in HBIG (194,195). Although no evidence suggests that S gene immunization escape mutants pose a threat to existing programs using hepatitis B vaccines (196), further studies and enhanced surveillance to detect the emergence of these variants are high priorities for monitoring the effectiveness of current vaccination strategies.

**Recommendations for Hepatitis B Vaccination of Infants, Children, and Adolescents**

This section outlines updated ACIP recommendations and associated implementation strategies for hepatitis B vaccina-
tion of infants, children, and adolescents. These recommendations have been summarized (Box 3).

**Prevention of Perinatal HBV Infection and Management of Pregnant Women**

**Recommendations**

**Prenatal HBsAg Testing**
- All pregnant women should be tested routinely for HBsAg during an early prenatal visit (e.g., first trimester) in each pregnancy, even if they have been previously vaccinated or tested.
- Women who were not screened prenatally, those who engage in behaviors that put them at high risk for infection (e.g., injection-drug use, having had more than one sex partner in the previous 6 months or an HBsAg-positive sex partner, evaluation or treatment for a sexually transmitted disease [STD], or recent or current injection-drug use) and those with clinical hepatitis should be tested at the time of admission to the hospital for delivery.
- All laboratories that provide HBsAg testing of pregnant women should use an FDA-licensed or -approved HBsAg test and should perform testing according to the manufacturer’s labeling, including testing of initially reactive specimens with a licensed neutralizing confirmatory test. When pregnant women are tested for HBsAg at the time of admission for delivery, shortened testing protocols may be used and initially reactive results reported to expedite administration of immunoprophylaxis to infants.
- Women who are HBsAg positive should be referred to an appropriate case-management program to ensure that their infants receive timely postexposure prophylaxis and follow-up (see Case-Management Programs to Prevent Perinatal HBV Infection). In addition, a copy of the original laboratory report indicating the pregnant woman’s HBsAg status should be provided to the hospital where delivery is planned and to the health-care provider who will care for the newborn.
- Women who are HBsAg positive should be provided with or referred for appropriate counseling and medical management (Appendix A). HBsAg-positive pregnant women should receive information concerning hepatitis B that discusses:
  - modes of transmission;
  - perinatal concerns (e.g., infants born to HBsAg-positive mothers may be breast fed);
  - prevention of HBV transmission to contacts, including the importance of postexposure prophylaxis for the newborn infant and hepatitis B vaccination for household, sexual, and needle-sharing contacts;
  - substance abuse treatment, if appropriate; and
  - medical evaluation and possible treatment of chronic hepatitis B.
- When HBsAg testing of pregnant women is not feasible (i.e., in remote areas without access to a laboratory), all infants should complete hepatitis B vaccine series at age 9–18 months.

**Management of Infants Born to Women Who Are HBsAg Positive**
- All infants born to HBsAg-positive women should receive single-antigen hepatitis B vaccine (Table 2) and HBIG.
(0.5 mL) ≤12 hours of birth, administered at different injection sites. The vaccine series should be completed according to a recommended schedule for infants born to HBsAg-positive mothers (Table 3). The final dose in the vaccine series should not be administered before age 24 weeks (164 days).

• For preterm infants weighing <2,000 g, the initial vaccine dose (birth dose) should not be counted as part of the vaccine series because of the potentially reduced immunogenicity of hepatitis B vaccine in these infants; 3 additional doses of vaccine (for a total of 4 doses) should be administered beginning when the infant reaches age 1 month (Tables 3 and 4).

• Postvaccination testing for anti-HBs and HBsAg should be performed after completion of the vaccine series, at age 9–18 months (generally at the next well-child visit). Testing should not be performed before age 9 months to avoid detection of anti-HBs from HBIG administered during infancy and to maximize the likelihood of detecting late HBV infection. Anti-HBc testing of infants is not recommended because passively acquired maternal anti-HBc might be detected in infants born to HBV-infected mothers to age 24 months.

— HBsAg-negative infants with anti-HBs levels ≥10 mIU/mL are protected and need no further medical management.

— HBsAg-negative infants with anti-HBs levels <10 mIU/mL should be revaccinated with a second 3-dose series and retested 1–2 months after the final dose of vaccine.

— Infants who are HBsAg positive should receive appropriate follow-up (Appendix A).

• Infants of HBsAg-positive mothers may be breast fed beginning immediately after birth.

• Although not indicated in the manufacturer’s package labeling, HBsAg-containing combination vaccines may be used for infants aged ≥6 weeks born to HBsAg-positive mothers to complete the vaccine series after receipt of a birth dose of single-antigen hepatitis B vaccine and HBIG.

Management of Infants Born to Women with Unknown HBsAg Status

• Women admitted for delivery without documentation of HBsAg test results should have blood drawn and tested as soon as possible after admission.

• While test results are pending, all infants born to women without documentation of HBsAg test results should receive the first dose of single-antigen hepatitis B vaccine (without HBIG) ≤12 hours of birth (Tables 2 and 3).

— If the mother is determined to be HBsAg positive, her infant should receive HBIG as soon as possible but no later than age 7 days, and the vaccine series should be completed according to a recommended schedule for infants born to HBsAg-positive mothers (Table 3).

— If the mother is determined to be HBsAg negative, the vaccine series should be completed according to a recommended schedule for infants born to HBsAg-negative mothers (Table 3).

— If the mother has never been tested to determine her HBsAg status, the vaccine series should be completed according to a recommended schedule for infants born to HBsAg-positive mothers (Table 3). Administration of HBIG is not necessary for these infants.

• Because of the potentially decreased immunogenicity of vaccine in preterm infants weighing <2,000 g, these infants should receive both single-antigen hepatitis B vaccine and HBIG (0.5 mL) if the mother’s HBsAg status cannot be determined ≤12 hours of birth. The birth dose of vaccine should not be counted as part of the 3 doses required to complete the vaccine series; 3 additional doses of vaccine (for a total of 4 doses) should be administered according to a recommended schedule on the basis of the mother’s HBsAg test result (Table 3).

Vaccination of Pregnant Women

• Pregnant women who are identified as being at risk for HBV infection during pregnancy (e.g., having more than one sex partner during the previous 6 months, been evaluated or treated for an STD, recent or current injection-drug use, or having had an HBsAg-positive sex partner) should be vaccinated.

• Pregnant women at risk for HBV infection during pregnancy should be counseled concerning other methods to prevent HBV infection.

Implementation

Delivery Hospital Policies and Procedures

• All delivery hospitals should implement policies and procedures (Box 4) to ensure 1) identification of infants born to HBsAg-positive mothers and infants born to mothers with unknown HBsAg status (see Prenatal HBsAg Testing), and 2) initiation of immunization for these infants. Such policies and procedures should include the following standing orders:

— for all pregnant women, review of HBsAg test results at the time of admission for delivery;

— for women who do not have a documented HBsAg test result, HBsAg testing as soon as possible after admission for delivery;
BOX 4. Delivery hospital policies and procedures to prevent perinatal HBV transmission

At time of admission for delivery
- Review hepatitis B surface antigen (HBsAg) status of all pregnant women.
- Record maternal HBsAg test results on both labor and delivery record and on infant’s delivery summary sheet.
- Perform HBsAg testing as soon as possible on women who
  — do not have a documented HBsAg test result,
  — were at risk for HBV infection during pregnancy (e.g., more than one sex partner in the previous 6 months, evaluation or treatment for a sexually transmitted disease, recent or current injection-drug use, or HBsAg-positive sex partner), or
  — had clinical hepatitis since previous testing.

After delivery

HBsAg-positive mothers and their infants
- Administer single-antigen hepatitis B vaccine and hepatitis B immune globulin (HBIG) to all infants born to HBsAg-positive mothers <12 hours after birth and record date and time of administration of HBIG and hepatitis B vaccine in infant’s medical record.
- Provide information regarding hepatitis B to HBsAg-positive mothers, including
  — advice that they may breastfeed their infants upon delivery;
  — modes of HBV transmission;
  — need for vaccination of their susceptible household, sexual, and needle-sharing contacts;
  — need for substance abuse treatment, if appropriate; and
  — need for medical management and possible treatment for chronic hepatitis B.

Mothers with unknown HBsAg status and their infants
- Administer single-antigen hepatitis B vaccine (without HBIG) to all infants born to mothers with unknown HBsAg status <12 hours after birth and record date and time of administration of hepatitis B vaccine on infant’s medical record.
- Alert infant’s pediatric health-care provider if an infant is discharged before the mother’s HBsAg test result is available; if the mother is determined to be HBsAg positive, HBIG should be administered to the infant as soon as possible, but no later than age 7 days.

All mothers and their infants
- Administer a dose of single-antigen hepatitis B vaccine to all infants weighing ≥2,000 g.
- Ensure that all mothers have been tested for HBsAg prenatally or at the time of admission for delivery and document test results.

At time infant is discharged
- Provide infant’s immunization record to mother and remind her to take it to the infant’s first visit to pediatric health-care provider.

— identification and management of all infants born to HBsAg-positive mothers;
— identification and management of all infants born to mothers with unknown HBsAg status; and
— for all infants, documentation on the infant’s medical record of maternal HBsAg test results, infant hepatitis B vaccine administration, and administration of HBIG (if appropriate).

- Delivery hospitals should enroll in the federally funded Vaccines for Children (VFC) program to obtain free hepatitis B vaccine for administration of the birth dose to newborns who are eligible (i.e., Medicaid eligible, American Indian or Alaska Native, underinsured, or uninsured).

Case-Management Programs to Prevent Perinatal HBV Infection
- States and localities should establish case-management programs (Box 5), including appropriate policies, procedures, laws, and regulations, to ensure that
  — all pregnant women are tested for HBsAg during each pregnancy, and
  — infants born to HBsAg-positive women and infants born to women with unknown HBsAg status receive recommended case management.

- The location of these programs and the methods by which they operate will depend on multiple factors (e.g., population density and annual caseload of HBsAg-positive women). Programs may be located in state or local health departments, private healthcare systems (e.g., health maintenance organizations), or institutions (e.g., correctional facility systems). Program administrators will need to work with prenatal care providers, delivery hospital staff, pediatric care providers, private healthcare systems, and health departments.

Universal Vaccination of Infants

Recommendations
- All infants should receive the hepatitis B vaccine series as part of the recommended childhood immunization schedule (Table 5 and Appendix B). (For recommendations on management of infants born to HBsAg-positive mothers and infants born to mothers with unknown HBsAg status, see Prevention of Perinatal HBV Infection and Management of Pregnant Women.)

- For all medically stable infants weighing ≥2,000 g at birth and born to HBsAg-negative mothers, the first dose of vaccine should be administered before hospital discharge. Only single-antigen hepatitis B vaccine should be used for the birth dose.
### BOX 5. Components of case-management programs to prevent perinatal hepatitis B virus infection

<table>
<thead>
<tr>
<th>Test all pregnant women for hepatitis B surface antigen (HBsAg)</th>
<th>Identify and manage infants born to mothers without HBsAg test results</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Health-care providers should test all pregnant women for HBsAg during each pregnancy.</td>
<td></td>
</tr>
<tr>
<td>• HBsAg testing should be incorporated into standard prenatal testing panels (e.g., blood type, human immunodeficiency virus [HIV] infection, Rh factor, rubella antibody titer, and syphilis infection) used by all health-care providers caring for pregnant women.</td>
<td></td>
</tr>
<tr>
<td>• Delivery hospitals should ensure that all pregnant or delivering women have been tested for HBsAg before hospital discharge.</td>
<td></td>
</tr>
<tr>
<td>• Reporting of HBsAg test status should be included on hospital-based electronic birth certificates or neonatal metabolic screening requests.</td>
<td></td>
</tr>
<tr>
<td><strong>Report and track HBsAg-positive women</strong></td>
<td></td>
</tr>
<tr>
<td>• All HBsAg-positive pregnant women and all women of childbearing age with HBsAg-positive laboratory results should be reported to state or local perinatal hepatitis B prevention programs.</td>
<td></td>
</tr>
<tr>
<td>• All HBsAg-positive pregnant women should be entered into case-management tracking systems.</td>
<td></td>
</tr>
<tr>
<td><strong>Provide prenatal HBsAg testing records to delivery hospitals</strong></td>
<td></td>
</tr>
<tr>
<td>• HBsAg test results should be included on all forms (hard copy, electronic) used by practitioners to record and transmit information regarding care during pregnancy.</td>
<td></td>
</tr>
<tr>
<td>• For all pregnant women, a copy of the original laboratory report of HBsAg test results should be transferred from the prenatal care provider to the delivery hospital.</td>
<td></td>
</tr>
<tr>
<td>• Practitioners should document that HBsAg-positive pregnant women have a copy of the original laboratory report, that a copy of the original laboratory report is transferred from the prenatal care provider to the delivery hospital, and that patients are informed of their HBsAg test status and advised to notify delivery staff.</td>
<td></td>
</tr>
<tr>
<td><strong>Identify and manage infants born to HBsAg-positive mothers</strong></td>
<td></td>
</tr>
<tr>
<td>• Delivery hospitals should implement policies and procedures to ensure identification and initiation of postexposure immunization of infants born to HBsAg-positive mothers (see Delivery Hospital Policies and Procedures).</td>
<td></td>
</tr>
<tr>
<td>• Delivery hospitals should document the date and time of birth and the date and time of administration of hepatitis B immune globulin (HBIG) and hepatitis B vaccine for all infants born to HBsAg-positive mothers.</td>
<td></td>
</tr>
<tr>
<td>• Delivery hospitals should implement policies and procedures to ensure identification and initiation of postexposure immunization of infants born to mothers with unknown HBsAg status at delivery (see Delivery Hospital Policies and Procedures).</td>
<td></td>
</tr>
<tr>
<td>• Delivery hospitals should document the date and time of birth, date and time of administration of hepatitis B vaccine, and maternal HBsAg test results for all infants born to mothers with unknown HBsAg status at the time of delivery.</td>
<td></td>
</tr>
<tr>
<td><strong>Complete the hepatitis B vaccine series</strong></td>
<td></td>
</tr>
<tr>
<td>• Practitioners should document the dates of administration of all doses of the hepatitis B vaccine series for all infants born to HBsAg-positive mothers.</td>
<td></td>
</tr>
<tr>
<td><strong>Complete postvaccination testing</strong></td>
<td></td>
</tr>
<tr>
<td>• Health-care providers should document the results of testing for HBsAg and antibody to hepatitis B surface antigen (anti-HBs) after completion of the hepatitis B vaccine series for all infants born to HBsAg-positive mothers.</td>
<td></td>
</tr>
<tr>
<td><strong>Monitor and evaluate the case management program</strong></td>
<td></td>
</tr>
<tr>
<td>• Annually, each program should track — the number of HBsAg-positive pregnant women; — the proportion of infants born to HBsAg-positive women receiving postexposure prophylaxis ≤12 hours of birth, third vaccine dose by age 6 months, and postvaccination serologic testing for HBsAg and anti-HBs; — the number of delivering women with unknown HBsAg status; and — the proportion of infants born to mothers with unknown HBsAg status receiving hepatitis B vaccine within 12 hours of birth.</td>
<td></td>
</tr>
<tr>
<td>• Programs should determine reasons for — &gt;10% difference between expected and identified number of HBsAg-positive pregnant women; — &lt;90% completion rates for HBIG and hepatitis B vaccine ≤12 hours of birth, third dose by age 6 months, and postvaccination testing for infants born to HBsAg-positive mothers; and — &lt;90% completion rates for hepatitis B vaccine ≤12 hours of birth for infants born to mothers with unknown HBsAg status.</td>
<td></td>
</tr>
</tbody>
</table>
On a case-by-case basis and only in rare circumstances, the first dose may be delayed until after hospital discharge for an infant who weighs ≥2,000 g and whose mother is HBsAg negative.

— When such a decision is made, a physician’s order to withhold the birth dose and a copy of the original laboratory report indicating that the mother was HBsAg negative during this pregnancy should be placed in the infant’s medical record.

— For infants who do not receive a first dose before hospital discharge, the first dose should be administered no later than age 2 months.

— Situations in which the birth dose should not be delayed include any high-risk sexual or drug-using practices of the infant’s mother during pregnancy (e.g., having had more than one sex partner during the previous 6 months or an HBsAg-positive sex partner, evaluation or treatment for an STD, or recent or current injection-drug use) and expected poor compliance with follow-up to initiate the vaccine series.

• Preterm infants weighing <2,000 g and born to HBsAg-negative mothers should have their first vaccine dose delayed until 1 month after birth or hospital discharge (Table 4). For these infants, a copy of the original laboratory report indicating that the mother was HBsAg negative during this pregnancy should be placed in the infant’s medical record.

• The vaccine series should be completed according to a recommended schedule with either single-antigen vaccine or a combination vaccine that contains the hepatitis B vaccine antigen (e.g., Hib-hepatitis B or DTaP-IPV-hepatitis B) (Table 2). The final dose in the vaccine series should not be administered before age 24 weeks (164 days).

• Administration of 4 doses of hepatitis B vaccine to infants is permissible in certain situations (e.g., when combination vaccines are administered after the birth dose).

• In populations with currently or previously high rates of childhood HBV infection (i.e., Alaska Natives; Pacific Islanders; and immigrant families from Asia, Africa, and other regions with intermediate or high endemic rates of infection [Figure 1 and Box 2]), the first dose of hepatitis B vaccine should be administered at birth and the final dose at age 6–12 months.

Implementation

• All delivery hospitals should implement standing orders for administration of hepatitis B vaccination as part of routine medical care of all medically stable infants weighing ≥2,000 g at birth (Box 4).

All delivery hospitals should implement policies and procedures for management of infants weighing <2,000 g at birth, including the following:

— ensuring initiation of postexposure immunization of infants born to HBsAg-positive mothers and infants born to mothers not screened for HBsAg prenatally (see Prevention of Perinatal HBV Infection and Management of Pregnant Women), and

— documentation of maternal HBsAg test results on the infant’s medical record.

• Prenatal care education should include information regarding the rationale for and importance of newborn hepatitis B vaccination.

• States are encouraged to adopt regulations or laws that require hepatitis B vaccination for entry into child care and also for entry into kindergarten and/or elementary school to ensure high vaccine coverage among infants and children.

Vaccination of Children and Adolescents Who Were Not Previously Vaccinated

Recommendations

• Hepatitis B vaccination is recommended for all children and adolescents aged <19 years.

• Children and adolescents who have not previously received hepatitis B vaccine should be vaccinated routinely at any age with an appropriate dose and schedule (Tables 2 and 5). Selection of a vaccine schedule should consider the need to achieve completion of the vaccine series. In all settings, vaccination should be initiated even though completion of the vaccine series might not be ensured.

Implementation

• To ensure high vaccination coverage among children and adolescents, the following measures are recommended:
  — All children aged 11–12 years should have a review of their immunization records and should complete the vaccine series if they were not previously vaccinated or were incompletely vaccinated.
  — All children and adolescents aged <19 years (including internationally adopted children) who were born in Asia, the Pacific Islands, Africa, or other intermediate- or high-endemic countries (Figure 1 and Box 2) or who have at least one parent who was born in one of these areas should have a review of their immunization records and should complete the vaccine series if they were not previously vaccinated or were incompletely vaccinated.
— States are encouraged to adopt regulations or laws that require hepatitis B vaccination before entry into middle school or its equivalent.

— Vaccination requirements should be considered for older high school students and for students before college entry, when feasible.

— States are encouraged to expand or implement immunization registries to include adolescents.

— Hepatitis B vaccine should be offered to all unvaccinated adolescents in settings that provide health-care services to this age group (Box 6), particularly those who engage in behaviors that place them at high risk for HBV infection.

BOX 6. Health-care settings in which hepatitis B vaccine should be offered to all unvaccinated children and adolescents

| Primary care clinics |
| Substance abuse treatment facilities |
| Family planning clinics |
| Institutions for the developmentally disabled |
| Juvenile correctional facilities |
| Nonresidential daycare facilities for the developmentally disabled |
| Sexually transmitted disease clinics |
| School-based clinics |

References


Note: Page 24 in the original MMWR article is a blank page. This has been omitted, and the next page is numbered (at the top) 25.
Appendix A

Case Finding and Management of Hepatitis B Surface Antigen (HBsAg)–Positive Persons During Delivery of Vaccination Services

Chronically infected persons are at high risk for chronic liver disease and are a major reservoir of hepatitis B virus (HBV) infection. Foreign-born persons, especially persons from Africa, Asia, and the Pacific Islands, have high* rates of chronic HBV infection. During delivery of recommended hepatitis B vaccination services (e.g., HBsAg screening of pregnant women and serologic testing to assess susceptibility), vaccination providers will identify persons who are HBsAg positive. These persons require counseling and medical management for chronic HBV infection to reduce their risk for chronic liver disease. Their susceptible household, sexual, and needle-sharing contacts also need to be vaccinated against hepatitis B.

Few programs have been implemented to identify HBsAg-positive persons, provide or refer these persons for appropriate medical management, and provide vaccination to their contacts (1). Extending these services to persons identified as HBsAg positive will help prevent serious sequelae in chronically infected persons and enhance vaccination strategies for elimination of HBV transmission. This Appendix addresses case finding and management of persons with chronic HBV infection in the context of vaccine delivery. The recommendations are not intended to represent a comprehensive prevention program for chronically infected persons.

Case Finding in the Context of Vaccination Service Delivery

- All foreign-born persons (including immigrants, refugees, asylum seekers, and internationally adopted children) born in Asia, the Pacific Islands, Africa, and other regions with high endemicity of HBV infection (Box A-1) should be tested for HBsAg, regardless of vaccination status.
- For all persons born in high-endemic countries who are applying for permanent U.S. residence, HBsAg screening and appropriate follow-up on the basis of HBsAg test results should be included as part of the required overseas premigration and domestic adjustment-of-visa status medical examination process (2).
- HBsAg-positive persons should be considered eligible for migration and adjustment-of-visa status and counseled and recommended for follow-up medical evaluation and management in U.S. resettlement communities.

---

**Box A-1. Geographic areas with high* hepatitis B virus endemicity**

- **Africa:** all countries except Algeria, Egypt, Libya, and Tunisia
- **South Asia:** all countries except Afghanistan, Bangladesh, Bhutan, India, Malaysia, Maldives, Nepal, Pakistan, and Sri Lanka
- **Western Pacific:** all countries except Australia, Guam, Japan, and New Zealand
- **Middle East:** Jordan and Saudi Arabia
- **Eastern Europe and Newly Independent States of the former Soviet Union:** Albania, Armenia, Azerbaijan, Bulgaria, Croatia, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan
- **Western Europe:** Malta
- **North America:** Alaska Natives and indigenous populations in Northern Canada and Greenland
- **South America:** Amazonian areas of Bolivia, Brazil, Columbia, Peru, and Venezuela

* Hepatitis B surface antigen prevalence of >8%.

---

- Providers should identify children born in high-endemic countries and provide HBsAg testing and follow-up in all settings that provide health care. Retesting of persons who were tested for HBsAg in other countries should be considered.
- Other persons who should be tested for HBsAg as part of vaccination services include:
  - all pregnant women (See Prevention of Perinatal HBV Infection and Management of Pregnant Women),
  - persons who receive prevaccination testing for susceptibility and who test positive for anti-HBc (See Pre-vaccination Testing for Susceptibility),
  - hemodialysis patients, and
  - nonresponders to vaccination (See Appendix B, Post-vaccination Testing for Serologic Response).

Management of Persons Identified as HBsAg Positive

- All persons with HBsAg-positive laboratory results should be reported to the state or local health department.
- To verify the presence of chronic HBV infection, HBsAg-positive persons should be retested. The absence of immu-
noglobulin M antibody to HBCAg or the persistence of HBsAg for 6 months indicates chronic HBV infection.

• Persons with chronic HBV infection should be referred for evaluation by a physician experienced in the management of chronic liver disease (3). Certain patients with chronic hepatitis B will benefit from early intervention with antiviral treatment or screening to detect hepatocellular carcinoma at an early stage.

• Household, sexual, and needle-sharing contacts of chronically infected persons should be identified. Unvaccinated sex partners and household and needle-sharing contacts should be tested for susceptibility to HBV infection (see Prevaccination Serologic Testing for Susceptibility) and should receive the first dose of hepatitis B vaccine immediately after collection of the blood sample for serologic testing. Susceptible persons should complete the vaccine series using an age-appropriate vaccine dose and schedule (see Tables 2 and 6) Persons who are not fully vaccinated should complete the vaccine series.

• Sex partners of HBsAg-positive persons should be counseled to use methods (e.g., condoms) to protect themselves from sexual exposure to infectious body fluids (e.g., semen or vaginal secretions) unless they have been demonstrated to be immune after vaccination (i.e., anti-HBs ≥10 mIU/mL) or previously infected (anti-HBc positive).

• To prevent or reduce the risk for transmission to others, HBsAg-positive persons should be advised concerning the risks for
  — perinatal transmission to infants born to HBsAg-positive women and the need for such infants to receive hepatitis B vaccine beginning at birth (see Prevention of Perinatal HBV Infection and Management of Pregnant Women) and
  — transmission to household, sexual, and needle-sharing contacts and the need for such contacts to receive hepatitis B vaccine.

• HBsAg-positive persons should also be advised to
  — use methods (e.g., condoms) to protect nonimmune sex partners from acquiring HBV infection from sexual activity until the sex partners can be vaccinated and immunity documented;
  — cover cuts and skin lesions to prevent the spread of infectious secretions or blood;
  — refrain from donating blood, plasma, tissue, or semen (organs may be donated to HBV-immune or chronically infected persons needing a transplant); and
  — refrain from sharing household articles (e.g., toothbrushes, razors, or personal injection equipment) that could become contaminated with blood.

• To protect the liver from further harm, HBsAg-positive persons should be advised to
  — avoid or limit alcohol consumption because of the effects of alcohol on the liver;
  — refrain from beginning to take any new medicines, including over-the-counter and herbal medicines, without consulting their health-care provider; and
  — obtain vaccination against hepatitis A if chronic liver disease is found to be present.

• When seeking medical or dental care, HBsAg-positive persons should be advised to inform those responsible for their care of their HBsAg status so they can be evaluated and their care managed appropriately.

• Other counseling messages:
  — HBV is not spread by breastfeeding, kissing, hugging, coughing, ingesting food or water, sharing eating utensils or drinking glasses, or casual contact.
  — Persons should not be excluded from school, play, child care, work, or other settings on the basis of their HBsAg status unless they are prone to biting (4).
  — Involvement with a support group might help patients cope with chronic HBV infection.

References

Appendix B
Immunization Management Issues

Hepatitis B Vaccine Dose and Administration

- Recommended vaccine doses vary by product, age of recipient, and needs of special populations (see Table 2). Administration of single-antigen or combination vaccine simultaneously with other childhood vaccines produces no clinically significant interference in antibody responses (1–13). Although the antigen contents of vaccines differ, vaccines made by different manufacturers are interchangeable, except for the 2-dose schedule used for adolescents aged 11–15 years, for which only Recombivax HB is approved. Combination vaccines are not approved for use as a birth dose because of potential suppression of the immune response to subsequent doses of the Haemophilus influenzae type b (Hib) component in Comvax (14) and possible decreased immunogenicity of the diphtheria component of Pediarix when administered at birth.
- Hepatitis B vaccine should be administered by intramuscular injection. Injection into the buttck is associated with decreased immunogenicity (15–18). Intradermal administration can result in a lower seroconversion rate and final concentration of antibody to hepatitis B surface antigen compared with intramuscular administration; limited data are available to assess long-term protection from this route of administration (19,20).
- The anterolateral thigh muscle is the recommended site of administration for neonates (aged <1 month) and infants (aged 1–12 months). For toddlers (aged 1–2 years) and older children, either the anterolateral thigh or the deltoid muscle may be used if the muscle mass is adequate. The deltoid muscle is the preferred site of administration for adolescents.
- For intramuscular injection, the needle should be long enough to reach the muscle mass and prevent vaccine from seeping into subcutaneous tissue, but not so long as to involve underlying nerves and blood vessels or bone (21). The appropriate needle length is usually 7/8” for neonates, 7/8”–1” for infants, and 7/8”–1 1/4” for toddlers, older children, and adolescents. A 22- to 25-gauge needle should be used.
- Hepatitis B vaccine administered by any route or site other than intramuscularly in the anterolateral thigh or deltoid muscle should not be counted as valid and should be repeated unless serologic testing indicates that an adequate response has been achieved (see Postvaccination Testing for Serologic Response).
- Hepatitis B vaccine and other vaccines administered during the same visit should be administered in different injection sites. When more than one injection must be administered in the same limb, the anterolateral thigh is usually the preferred site, with injections separated by 1”–2” to avoid overlap in local reactions.
- For persons at risk for hemorrhage (e.g., persons with hemophilia), the risk of bleeding after intramuscular injection can be minimized by use of a 23-gauge (or smaller) needle, application of direct pressure to the injection site for ≥2 minutes, and administration of vaccine immediately after infusion of coagulation factor. Subcutaneous administration of vaccine can be considered for these persons but might result in lower response and an increased local reaction.
- Hepatitis B vaccine should be stored at 35°–46° F (2°–8° C) and should not be frozen.
- A vaccine information statement (VIS) must be provided to recipients of hepatitis B vaccine. The National Childhood Vaccine Injury Act of 1986 (42 U.S.C. § 300aa-26) requires vaccine providers to give a copy of the most current vaccine-specific VIS to all recipients (children or their guardians) of vaccines that are included on the National Vaccine Injury Compensation Program table maintained by the Health Resources and Services Administration (available at http://www.hrsa.gov). Hepatitis B vaccine is included on this table. The most current VIS for hepatitis B vaccine is available at http://www.cdc.gov/nip/publications/vis. Statements in languages other than English are available from the Immunization Action Coalition at http://www.immunize.org.

Hepatitis B Immune Globulin (HBIG) Dose and Administration

- The standard dose of HBIG is 0.5 mL for postexposure prophylaxis of infants born to hepatitis B surface antigen (HBsAg)–positive women and 0.06 mL/kg for all other applications.
- HBIG may be administered simultaneously with hepatitis B vaccine but in a different injection site.
- HBIG is administered by intramuscular injection. For neonates (aged <1 month) and infants (aged 1–12 months),
HBIG should be administered intramuscularly in the anterolateral thigh using a 22–25-gauge needle. The appropriate needle length is usually 5/8” for neonates and 7/8”–1” for infants. For older children and adolescents, an appropriate muscle mass (i.e., deltoid or gluteal) should be chosen in which to deliver the larger volumes of HBIG required for these age groups by using a needle length appropriate for the person’s age and size (21).

- Vaccination with certain live-virus vaccines (measles, mumps, rubella, and varicella) should be deferred for at least 3 months after administration of HBIG because HBIG can inhibit the response to these vaccines (21).
- HBIG should be stored at 35°–46° F (2°–8° C) and should not be frozen.

Unknown or Uncertain Vaccination Status

- A reliable vaccination history is defined as a written, dated record (personal, school, physician, or immunization registry) of each dose of vaccine, of a complete series.
- In the majority of clinical practice settings and in situations when postexposure prophylaxis is indicated (see Appendix C), providers should accept only written and dated records (e.g., personal, school, physician, or immunization registry) as evidence of vaccination. Although vaccinations should not be postponed if records cannot be located, providers should try to locate missing records by contacting previous health-care providers and searching for personally held records.
- Persons whose records cannot be located should be considered susceptible and started or continued on the age-appropriate vaccine schedule.
- Persons who reside in the United States but were vaccinated in other countries should be considered fully vaccinated if they have written documentation of ≥3 doses of vaccine administered at recommended minimum intervals, including the third dose at age ≥24 weeks. If they were not vaccinated according to recommended minimum intervals, they should be revaccinated (see Minimum Dosing Intervals and Management of Persons Who Were Incorrectly Vaccinated). Persons without written documentation of full vaccination should complete the age-appropriate vaccine series.

Interrupted Vaccine Schedules

- When the hepatitis B vaccine schedule is interrupted, the vaccine series does not need to be restarted.
- If the series is interrupted after the first dose, the second dose should be given as soon as possible, and the second and third doses should be separated by an interval of at least 8 weeks.
- If only the third dose is delayed, it should be administered as soon as possible, after age 24 weeks (164 days).
- It is not necessary to restart the vaccine series for infants switched from one vaccine brand to another, including combination vaccines.

Minimum Dosing Intervals and Management of Persons Who Were Incorrectly Vaccinated

- The third dose of vaccine must be administered at least 8 weeks after the second dose and should follow the first dose by at least 16 weeks; the minimum interval between the first and second doses is 4 weeks. In infants, administration of the final dose is not recommended before age 24 weeks (164 days).
- Inadequate doses of hepatitis B vaccine (see Table 2) or doses received after a shorter-than-recommended dosing interval should be readministered.

Accelerated Vaccine Schedules

- The Food and Drug Administration (FDA) has not approved accelerated schedules in which hepatitis B vaccine is administered more than once in a month. If clinicians choose to use an accelerated schedule (i.e., doses at days 0, 7, and 14 days), the patient should also receive a booster dose at least 6 months after the start of the series to promote long-term immunity.

Hemodialysis Patients and Other Immunocompromised Persons

- Standard hepatitis B vaccine doses (see Table 2) are approved by FDA for vaccination of all persons aged <20 years. For hemodialysis patients and other immunocompromised persons, higher doses might be more immunogenic, but no specific recommendations have been made.
- Serologic testing of hemodialysis patients and other immunocompromised persons is recommended 1–2 months after administration of the final dose of the primary vaccine series to determine the need for revaccination (see Postvaccination Testing for Serologic Response). In addition, booster doses of vaccine might be needed (see Booster Doses).
Prevaccination Serologic Testing for Susceptibility

- Because of the low prevalence of HBV infection among infants, children, and adolescents born in the United States, prevaccination testing for susceptibility usually is not indicated for these age groups.
- Prevaccination testing for susceptibility is recommended for unvaccinated household, sexual, and needle-sharing contacts of HBsAg-positive persons.
- Anti-HBc is the test of choice for prevaccination testing.
- Persons tested for anti-HBc and found to be anti-HBc negative are susceptible and should complete the vaccine series.
- Persons found to be anti-HBc positive should be tested for HBsAg. HBsAg testing may be performed on the same specimen collected for anti-HBc testing. If the HBsAg test result is positive, the person should receive appropriate management (see Appendix A).
- In most situations, the first vaccine dose should be administered immediately after collection of the blood sample for serologic testing.

Postvaccination Testing for Serologic Response

Recommendations for postvaccination testing of infants born to HBsAg-positive women are provided in this report (see Management of Infants Born to Women Who Are HBsAg Positive). This section provides recommendations for postvaccination testing of other persons.
- Serologic testing for immunity is not necessary after routine vaccination of infants, children, or adolescents.
- Testing after vaccination is recommended only for the following persons whose subsequent clinical management depends on knowledge of their immune status:
  - health-care workers;
  - chronic hemodialysis patients, HIV-infected persons, and other immunocompromised persons (e.g., hematopoietic stem-cell transplant recipients or persons receiving chemotherapy), to determine the need for revaccination and the type of follow-up testing; and
  - sex partners of HBsAg-positive persons, to determine the need for revaccination and the need for other methods of protection against HBV infection.
- Testing should be performed 1–2 months after administration of the last dose of the vaccine series by using a method that allows determination of a protective level of anti-HBs (≥10 mIU/mL).

- Persons found to have anti-HBs levels of ≥10 mIU/mL after the primary vaccine series are considered to be immune.
  - Immunocompetent persons have long-term protection and do not need further periodic testing to assess anti-HBs levels.
  - Immunosuppressed persons might need annual testing to assess anti-HBs levels (see Booster Doses).
- Persons found to have anti-HBs levels of <10 mIU/mL after the primary vaccine series should be revaccinated. Administration of three doses on an appropriate schedule (Table 5), followed by anti-HBs testing 1–2 months after the third dose, is usually more practical than serologic testing after one or more doses of vaccine.
- Persons who do not respond to revaccination should be tested for HBsAg.
  - If the HBsAg test result is positive, the persons should receive appropriate management, and any household, sexual, or needle-sharing contacts should be identified and vaccinated (see Appendix A).
  - Persons who test negative for HBsAg should be considered susceptible to HBV infection and should be counseled about precautions to prevent HBV infection and the need to obtain HBIG postexposure prophylaxis for any known or likely parenteral exposure to HBsAg-positive blood (see Appendix C).

Booster Doses

- Booster doses are not recommended for persons with normal immune status who were vaccinated as infants, children, or adolescents. Serologic testing is not recommended to assess antibody levels in any age group, except in specific circumstances (see Postvaccination Testing for Serologic Response).
- For hemodialysis patients, the need for booster doses should be assessed by annual antibody to hepatitis B surface antigen (anti-HBs) testing. A booster dose should be administered when anti-HBs levels decline to <10 mIU/mL.
- For other immunocompromised persons (e.g., HIV-infected persons, hematopoietic stem cell transplant recipients, and persons receiving chemotherapy), the need for booster doses has not been determined. Annual anti-HBs testing and booster doses when anti-HBs levels decline to <10 mIU/mL should be considered in persons with an ongoing high risk for exposure.
References
15. CDC. Suboptimal response to hepatitis B vaccine given by injection into the buttock. MMWR 1985;34:105–8,113.
Appendix C
Postexposure Prophylaxis of Persons with Discrete Identifiable Exposures to Hepatitis B Virus (HBV)

This appendix provides recommendations for management of persons who are exposed to HBV through a discrete, identifiable exposure to blood or body fluids that contain blood. Recommendations for management of infants born to mothers who test positive for hepatitis B surface antigen (HBsAg)-positive mothers are provided in this report (see Prevention of Perinatal HBV Transmission and Management of Pregnant Women).

HBsAg-Positive Source

- Unvaccinated persons (Table C-1) or persons known not to have responded to a complete hepatitis B vaccine series should receive both hepatitis B immune globulin (HBIG) and hepatitis B vaccine as soon as possible after exposure (preferably <24 hours). For sexual exposures, HBIG should not be administered more than 14 days after exposure. Hepatitis B vaccine may be administered simultaneously with HBIG in a separate injection site. The hepatitis B vaccine series should be completed using the age-appropriate vaccine dose and schedule (see Tables 2 and 3).

- Persons who are in the process of being vaccinated but who have not completed the vaccine series should receive the appropriate dose of HBIG and should complete the vaccine series.

- Children and adolescents who have written documentation of a complete hepatitis B vaccine series and who were not vaccinated should receive a single vaccine booster dose.

Source with Unknown HBsAg Status

- Unvaccinated persons (Table C-1) should receive the hepatitis B vaccine series with the first dose initiated as soon as possible after exposure, preferably <24 hours. The vaccine series should be completed using the age-appropriate dose and schedule (see Tables 2, 3, and 5).

- Persons who are not fully vaccinated should complete the vaccine series.

- Children and adolescents with written documentation of a complete hepatitis B vaccine series require no further treatment.

TABLE C-1. Guidelines for postexposure immunoprophylaxis of unvaccinated persons who are exposed to blood or blood fluids that contain blood

<table>
<thead>
<tr>
<th>Cause</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discrete exposure to an HBsAg-Positive source</td>
<td></td>
</tr>
<tr>
<td>Pericutaneous (e.g., bite, needlestick) or mucosal exposure to HBsAg-positive blood or body fluids that contain blood</td>
<td>Administer hepatitis B vaccine and hepatitis B immune globulin (HBIG)†</td>
</tr>
<tr>
<td>Sexual or needle-sharing contact of an HBsAg-positive person</td>
<td>Administer hepatitis B vaccine and HBIG†</td>
</tr>
<tr>
<td>Victim of sexual assault/abuse who is HBsAg-positive</td>
<td></td>
</tr>
<tr>
<td>Discrete exposure to a source with unknown HBsAg status</td>
<td></td>
</tr>
<tr>
<td>Victim of sexual assault/abuse by a perpetrator with unknown HBsAg status</td>
<td>Administer hepatitis B vaccine†</td>
</tr>
<tr>
<td>Percutanueous (e.g., bite or needlestick) or mucosal exposure to blood or body fluids that contain blood from a source with unknown HBsAg status</td>
<td>Administer hepatitis B vaccine†</td>
</tr>
</tbody>
</table>

†Hepatitis B surface antigen.
†Immunoprophylaxis should be administered as soon as possible, preferably <24 hours. Studies are limited on the maximum interval after exposure during which postexposure prophylaxis is effective, but the interval is unlikely to exceed 7 days for percutaneous exposures and 14 days for sexual exposures. The hepatitis B vaccine series should be completed.
## Glossary

### Terms and Abbreviations Used in This Report

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACIP</td>
<td>Advisory Committee on Immunization Practices</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>Anti-HBc</td>
<td>antibody to hepatitis B core antigen</td>
</tr>
<tr>
<td>Anti-HBe</td>
<td>antibody to hepatitis B e antigen</td>
</tr>
<tr>
<td>Anti-HBs</td>
<td>antibody to hepatitis B surface antigen</td>
</tr>
<tr>
<td>DTaP</td>
<td>diphtheria and tetanus toxoids and acellular pertussis adsorbed</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>HBcAg</td>
<td>hepatitis B core antigen</td>
</tr>
<tr>
<td>HBeAg</td>
<td>hepatitis B e antigen</td>
</tr>
<tr>
<td>HBIG</td>
<td>hepatitis B immune globulin</td>
</tr>
<tr>
<td>HBsAg</td>
<td>hepatitis B surface antigen</td>
</tr>
<tr>
<td>HBV</td>
<td>hepatitis B virus</td>
</tr>
<tr>
<td>HCC</td>
<td>hepatocellular carcinoma</td>
</tr>
<tr>
<td>HCV</td>
<td>hepatitis C virus</td>
</tr>
<tr>
<td>Hib</td>
<td><em>Haemophilus influenzae</em> type b</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>IgM</td>
<td>immunoglobulin M</td>
</tr>
<tr>
<td>IPV</td>
<td>inactivated poliovirus</td>
</tr>
<tr>
<td>MS</td>
<td>multiple sclerosis</td>
</tr>
<tr>
<td>NHANES</td>
<td>National Health and Nutrition Examination Survey</td>
</tr>
<tr>
<td>VAERS</td>
<td>Vaccine Adverse Events Reporting System</td>
</tr>
<tr>
<td>VSD</td>
<td>Vaccine Safety Datalink</td>
</tr>
</tbody>
</table>
Advisory Committee on Immunization Practices

Membership List, June 2005

**Chairman:** Myron J. Levin, MD, Professor of Pediatrics and Medicine, University of Colorado Health Sciences Center, Denver, Colorado.

**Executive Secretary:** Larry Pickering, MD, National Immunization Program, CDC, Atlanta, Georgia.

**Members:** Jon S. Abramson, MD, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Ban Mishu Allos, MD, Vanderbilt University School of Medicine, Nashville, Tennessee; Guthrie S. Bikker, MD, New York State Department of Health, Albany, New York; Judith Campbell, MD, Baylor College of Medicine, Houston, Texas; Reginald Finger, MD, Focus on the Family, Colorado Springs, Colorado; Janet Gildsdorf, MD, University of Michigan, Ann Arbor, Michigan; Tracy Lieu, MD, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Massachusetts; Edgar Marcuse, MD, Children's Hospital and Regional Medical Center, Seattle, Washington; Julia Morita, MD, Chicago Department of Health, Chicago, Illinois; Gregory Poland, MD, Mayo Clinic College of Medicine, Rochester, Minnesota; John B. Salamone, National Italian American Foundation, Washington, DC; Patricia Stinchfield, Children's Hospital and Clinics, St. Paul, Minnesota; John J. Treanor, MD, University of Rochester School of Medicine and Dentistry, Rochester, New York; Robin Womeodou, MD, University of Tennessee Health Sciences Center, Memphis, Tennessee.

**Ex-Officio Members:** James E. Cheek, MD, Indian Health Service, Albuquerque, New Mexico; Wayne Hachey, DO, Department of Defense, Falls Church, Virginia; Geoffrey S. Evans, MD, Health Resources and Services Administration, Rockville, Maryland; Bruce Gellin, MD, National Vaccine Program Office, Washington, DC; Linda Murphy, Centers for Medicare and Medicaid Services, Baltimore, Maryland; George T. Caizlin, MD, National Institutes of Health, Bethesda, Maryland; Norman Baylot, MD, Food and Drug Administration, Bethesda, Maryland; Kristin Lee Nichol, MD, Department of Veterans Affairs, Minneapolis, Minnesota.

**Liaison Representatives:** American Academy of Family Physicians, Jonathan Temte, MD, Claremore, New York, and Richard Clover, MD, Louisville, Kentucky; American Academy of Pediatrics, Margaret Rennels, MD, Baltimore, Maryland, and Carol Baker, MD, Houston, Texas; America's Health Insurance Plans, Andrea Gelzer, MD, Hartford, Connecticut; American College Health Association, James C. Turner, MD, Charlottesville, Virginia; American College of Obstetricians and Gynecologists, Stanley Gall, MD, Louisville, Kentucky; American College of Physicians, Kathleen Neuill, MD, Seattle, Washington; American Medical Association, Lijen Tan, PhD, Chicago, Illinois; American Pharmacists Association, Stephen L. Foster, PharmD, Memphis, Tennessee; Association of Teachers of Preventive Medicine, W. Paul McKinney, MD, Louisville, Kentucky; Biotechnology Industry Organization, Clement Lewin, PhD, Cambridge, Massachusetts; Canadian National Advisory Committee on Immunization, Monica Naus, MD, Vancouver, British Columbia; Health Care Infection Control Practices Advisory Committee, Steve Gordon, MD, Cleveland, Ohio; Infectious Diseases Society of America, Samuel L. Katz, MD, Durham, North Carolina, and William Schaffner, MD, Nashville, Tennessee; London Department of Health, David M. Salisbury, MD, London, United Kingdom; National Association of County and City Health Officials, Nancy Bennett, MD, Rochester, New York; National Coalition for Adult Immunization, David A. Neumann, PhD, Bethesda, Maryland; National Immunization Council and Child Health Program, Mexico, Romeo Rodriguez, Mexico City; Mexico; National Medical Association, Dennis A. Brooks, MD, Baltimore, Maryland; National Vaccine Advisory Committee, Charles Helms, MD, PhD, Iowa City, Iowa; Pharmaceutical Research and Manufacturers of America, Damian A. Braga, Swiftwater, Pennsylvania; and Society for Adolescent Medicine, Amy Middleman, MD, Houston, Texas.

**ACIP Hepatitis Vaccines Working Group**

**Chair:** Tracy Lieu, MD, Boston, Massachusetts.

**Members:** Jon Abramson, MD, Winston-Salem, North Carolina; Beth Bell, MD, Atlanta, Georgia; James E. Cheek, MD, Albuquerque, New Mexico; Anthony Fiore, MD, Atlanta, Georgia; Stephen Feinstone, MD, Bethesda, Maryland; Robert Freuchen, MD, Torrance, California; Stanley Gall, MD, Louisville, Kentucky; Janet Gildsdorf, MD, Ann Arbor, Michigan; Steve Gordon, MD, Cleveland, Ohio; Samuel L. Katz, MD, Durham, North Carolina; Edgar Marcuse, MD, Seattle, Washington; Ban Mishu Allos, MD, Nashville, Tennessee; Eric Mast, MD, Atlanta, Georgia; Julia Morita, MD, Chicago, Illinois; William Schaffner, MD, Nashville, Tennessee; Deborah Wesler, MD, Minneapolis, Minnesota.
The following article, published in *Pediatrics* in April 2010, reports on a survey of perinatal hepatitis B prevention policies in 190 delivery hospitals across the United States. The study examined how well hospitals implemented national ACIP recommendations for perinatal hepatitis B virus (HBV) prevention. Survey results reveal serious gaps in hospital policies and practices regarding perinatal HBV transmission. The study concludes that "efforts to avoid medical errors through appropriate implementation and monitoring of hospital practices are needed to eliminate perinatal HBV transmission."

The online version of this article, along with updated information and services, is located on the World Wide Web at: http://pediatrics.aappublications.org/content/125/4/704.full.html
Gaps in Hospital Policies and Practices to Prevent Perinatal Transmission of Hepatitis B Virus

WHAT'S KNOWN ON THIS SUBJECT: In the United States, an estimated 1.4 million people have chronic HBV infection, causing 2000 to 4000 deaths annually. Newborn HepB administration is a key intervention to prevent perinatal HBV transmission and morbidity and mortality caused by chronic HBV infection.

WHAT THIS STUDY ADDS: This study examined how well national recommendations for perinatal HBV prevention advocated by the CDC and the ACIP are implemented by hospitals. It also reveals considerable gaps in hospital policies and practices that need to be addressed.

abstract

OBJECTIVE: The objective of this study was to examine hospital policies and practices to prevent perinatal transmission of hepatitis B virus (HBV) in the United States and to identify gaps.

METHODS: In March 2006, a nationally representative sample of 242 delivery hospitals in the 50 states, District of Columbia, and Puerto Rico (with at least 100 annual births) were surveyed about hospital perinatal hepatitis B prevention policies and asked to review paired maternal–infant medical records for 25 consecutive live births. Main outcome measures were hospital policies related to the prevention of perinatal transmission of hepatitis B and the proportion of infants who received recommended care.

RESULTS: A total of 190 of 242 hospitals responded to the survey and completed medical record reviews for 4762 mothers and 4766 infants. The proportion of hospitals that reported each of the 8 policies examined ranged from 63.0% to 80.6%. Among infants who were born to the 18 hepatitis B surface antigen (HBsAg)-positive women with documented prenatal test results, 62.1% received both hepatitis B vaccine and hepatitis B immunoglobulin within 12 hours, but 13.7% were unvaccinated and 19.7% did not receive hepatitis B immunoglobulin before hospital discharge. Among infants who were born to 320 women with unknown HBsAg status, only 52.4% were vaccinated within 12 hours of birth and 20.1% were unvaccinated before discharge. Among infants who were born to HBsAg-negative mothers, 89.1% received the hepatitis B vaccine before hospital discharge. The strongest predictor of vaccine administration was having a written hospital policy for newborn hepatitis B vaccination.

CONCLUSIONS: These findings indicate that significant gaps persist in hospital policies and practices to prevent perinatal HBV transmission in the United States. Efforts to avoid medical errors through appropriate implementation and monitoring of hospital practices are needed to eliminate perinatal HBV transmission. Pediatrics 2010;125:704–711

AUTHORS: Bayo C. Willis, MPH,* Pascale Wortley, MD, MPH,* Susan A. Weng, MD, MPH,† Lisa Jacques-Correll, MSW,‡ and Fan Zhang, PhD, MD, MPH‡

*Immunization Services Division and ‡Global Immunization Division, National Center for Immunization and Respiratory Diseases, and ¶National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia

KEY WORDS
immunization, perinatal hepatitis B virus, hepatitis B vaccine

ABBREVIATIONS
HBV—hepatitis B virus
CDC—Centers for Disease Control and Prevention
HBsAg—hepatitis B surface antigen
PEP—postexposure prophylaxis
HepB—hepatitis B vaccine
HBIG—hepatitis B immunoglobulin
ACIP—Advisory Committee on Immunization Practices
AMA—American Hospital Association
CI—confidence interval
NIIS—National Immunization Survey

All authors are responsible for the reported research. All authors participated in the concept and design, analysis and interpretation of data, and drafting or revising of the manuscript and have approved the manuscript as submitted.

This work was presented at the Hepatitis B Coordinators Meeting, May 2, 2007, Atlanta, GA; and the 41st National Immunization Conference, March 5, 2007, Kansas City, MO.

The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

The assessment protocol was reviewed by the CDC National Center for Immunization and Respiratory Diseases Human Subjects Contact and determined to be a nonresearch assessment of public health practice.

www.pediatrics.org/cgi/doi/10.1542/peds.2006-1831
doi:10.1542/peds.2006-1831

Accepted for publication Nov 5, 2009

Address correspondence to Bayo C. Willis, MPH, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS E22, Atlanta, GA 30333. E-mail: bwillis@cdc.gov

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).
Copyright © 2010 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.
In the United States, an estimated 1.4 million people have chronic hepatitis B virus (HBV) infection, which is the underlying cause of 2000 to 4000 deaths annually. Two primary modes of HBV transmission occur during infancy: infected mother to newborn during delivery and infected household contact to infant. In contrast to adults with an ~5% risk for chronic HBV infection once infected, infants have an ~90% risk for developing chronic HBV infection and when chronically infected have a 25% risk for dying prematurely of cirrhosis or liver cancer. An estimated 24 000 HBV-infected US women give birth annually (Centers for Disease Control and Prevention [CDC], unpublished data, 2004). Prenatal screening of all pregnant women is recommended to identify hepatitis B surface antigen (HBsAg)-positive women before giving birth to ensure that their newborns can receive post-exposure prophylaxis (PEP). PEP includes the administration of hepatitis B vaccine (HepB) and hepatitis B immunoglobulin (HBIG) to newborns within 24 hours of birth and is 85% to 95% effective in preventing HBV transmission; HepB administration alone within the same time frame is 70% to 95% effective. Hepatitis B vaccination of newborns also provides preexposure protection to infants born to uninfected women when, if HBV exposure were to occur, the risk for developing chronic HBV infection is greatest. Newborn HepB administration is a key intervention to prevent perinatal HBV transmission and the subsequent morbidity and mortality that are caused by chronic HBV infection.

Despite the availability of PEP, infants continue to become infected. Approximately 40 to 90 perinatal HBV infections are reported to the CDC annually, although the true number of annual perinatal HBV infections may be 10 to 20 times higher. Perinatal HBV infections may occur as a result of various health care errors, including prenatal testing and reporting, failure to test all women who are admitted to delivery hospitals without prenatal HBsAg test results, lapses in reporting and documentation of HBsAg test results in maternal and newborn medical records, and failure to administer timely PEP.

The delivery hospital is the critical point for implementing perinatal HBV prevention activities; it is the safety net for ensuring that HBV-infected women are identified at delivery and it is where time-sensitive PEP must be delivered to the newborn. Delivery hospitals also play an important role in reporting HBsAg-positive women to health departments to ensure that infants complete the HepB series, undergo postvaccination serologic testing, and, if infected, are referred for evaluation and care. In December 2005, the Advisory Committee on Immunization Practices (ACIP) published recommendations to address the remaining challenges in prevention of perinatal transmission of HBV. To assess hospital policies and practices pertaining to perinatal HBV prevention, we conducted a nationally representative assessment that included a survey of hospital policies and medical record reviews.

**METHODS**

**Sample Selection**

The target population included all delivery hospitals in the 50 states, District of Columbia, and Puerto Rico as identified in the 2003 American Hospital Association (AHA) annual survey. Fifty-two percent of all hospitals (n = 3102) were eligible for selection based on number of births (>100 annually), accounting for 99.5% of births reported by hospitals in the AHA survey. With simple random sampling, a sample size of 200 hospitals was needed to estimate the proportion of hospitals reporting a given policy with a 95% confidence interval (CI) ± 7 percentage points. We allocated the sample size across 51 strata (50 states plus 1 stratum containing Washington, DC, and Puerto Rico) proportional to the number of hospitals in each stratum. When the number of hospitals allocated to a given stratum was <2, the selection of 2 was forced to calculate variance estimation on the basis of the sample design. We sampled 254 hospitals to allow for an ~80% response rate. Hospitals were contacted to verify provision of delivery services and to identify a contact person for survey receipt. Twelve hospitals did not provide delivery services, leaving a final sample of 242.

**Hospital Policy Survey**

The hospital policy survey was sent in March 2006 to nursing supervisors or clinical nurse managers of the selected hospital nurseries. The survey ascertained whether written policies regarding the following aspects of perinatal HBV prevention existed: review of maternal HBsAg test results during admission to labor and delivery units, testing on admission for women without documented prenatal HBsAg test results, management of infants who were born to women of HBsAg-positive and unknown status, and HepB administration to all newborns before discharge. Additional characteristics such as geographic location (ie, rural or urban [outside or within a metropolitan statistical area]), hospital affiliation type (medical school/residency training programs) and hospital funding type (for profit/not for profit) were obtained from the AHA survey.

**Medical Record Review**

Each sampled hospital was asked to review paired maternal and infant medical records for 25 consecutive
live births between October 2005 and March 2006. Maternal medical record data collected included demographics (age, race/ethnicity, health insurance type), attending provider type, documentation of results of HBsAg testing during pregnancy and on admission, and admission time/date. Data collected from the infant medical record included time/date of birth, birth weight, administration time/date of infant HepB and HBIG, and documentation of maternal HBsAg test result.

**Data Collection**

Hospital survey and medical record data were collected by the designated hospital contact, state or local health department staff, or, in the majority of cases, a combination of both. The majority of participating health department staff provided assistance by conducting follow-up telephone calls to ensure survey receipt and completion.

**Data Analysis**

We conducted the following descriptive analyses: (1) prevalence of policies regarding prevention of perinatal HBV transmission; (2) factors that were associated with prenatal testing; (3) prevalence of maternal HBV infection; (4) HepB and HBIG receipt within 12 hours of delivery for infants who were born to women with HBsAg-positive or unknown status, according to ACIP recommendations; and (5) maternal and facility characteristics associated with HepB receipt at birth. We also compared maternal HBsAg test results that were documented in the maternal medical record from prenatal and on-admission testing, as well as maternal results that were documented in the infant’s medical record.

Among mother–infant pairs with any mention of a positive maternal HBsAg test result, we defined 2 subsets. First, for estimation of the national prevalence of HBV infection, pregnant women were considered infected when they had documentation of a positive HBsAg test result prenatally or on admission and when there were no contradictory results in any records (eg, women who were HBsAg-positive prenatally but HBsAg-negative according to infant medical record were excluded). Second, for assessment of management of infants of HBsAg-positive mothers who were identified prenatally, data on all infants whose mothers had a documented HBsAg-positive prenatal test result were included.

Hospital survey data were weighted according to inverse probability of hospital selection and adjusted for nonresponse. For data analysis of mother–infant pairs, hospitals were identified as primary sampling units. Weights were calculated according to the number of annual live births in the respective hospitals. Analyses were conducted by using SUDAAN 9.0 to account for the stratified survey design. Weighted proportions and raw numbers are reported throughout.

**RESULTS**

**Response Rate**

Of 242 sampled hospitals, 190 (78.5%) completed the policy survey and medical record review. Hospital response rates by state ranged from 0% to 100% (100% of sampled hospitals in 32 states, 75%–99% in 8 states, 50%–74% in 8 states, 28% in 1 state, and 0% [among 12 hospitals] in 3 states). The median number of responding hospitals by state was 3 (range: 1–10). There were no statistically significant differences between responding and nonresponding hospitals regarding annual number of live births, hospital funding type (profit/not for profit) and urban/rural location. Medical record reviews were completed for 4762 mothers and 4786 infants (24 twins) who were born January 2005 through December 2006.

**Policies for Perinatal Hepatitis B Prevention**

The proportion of hospitals reporting each of the 8 policies examined ranged from 63.0% to 80.6% (Table 1). Most hospitals reported having policies for administration of HBIG (77.2% [95% CI: 70.7–82.6]) and HepB to infants who were born to HBV-infected women (80.6% [95% CI: 74.1–85.7]). Policies for testing on admission of women who were admitted with unknown HBsAg test results (63.0% [95% CI: 56.0–69.4]) and policies for universal HepB administration to newborns before hospital discharge (67% [95% CI: 59.1–73.5]) were reported least frequently.

**Maternal Characteristics and HBsAg Screening**

The majority of the 4762 women were white, privately insured, and 18 to 25 years of age (Table 2). Prenatal HBsAg test results were documented in 92.6% (95% CI: 90.4–94.3) of maternal medical records and varied little by demographic characteristic. HBsAg test results were documented by copy of the laboratory report in 12.8% (95% CI: 9.6–16.9) of maternal medical records reviewed; documentation in the re-

### TABLE 1

<table>
<thead>
<tr>
<th>Policy</th>
<th>n</th>
<th>Wt% (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review prenatal HBsAg test on admission</td>
<td>133</td>
<td>72.9 (68.3–78.6)</td>
</tr>
<tr>
<td>Test pregnant women on admission if no documented HBsAg test result</td>
<td>118</td>
<td>63.9 (56.0–69.4)</td>
</tr>
<tr>
<td>Give HBIG to exposed infants within 12 h</td>
<td>145</td>
<td>77.2 (70.7–82.6)</td>
</tr>
<tr>
<td>Give hepatitis B vaccine to exposed infants within 12 h</td>
<td>152</td>
<td>80.6 (74.1–85.7)</td>
</tr>
<tr>
<td>Give HepB to infants of mothers of unknown status within 12 h</td>
<td>153</td>
<td>70.5 (63.5–76.5)</td>
</tr>
<tr>
<td>Universal hepatitis B vaccination of newborns before hospital discharge</td>
<td>127</td>
<td>67.0 (59.1–73.5)</td>
</tr>
</tbody>
</table>
remaining 79.8% of maternal records was through clinical notes. Of 318 women without a documented prenatal test result, 57.3% (95% CI: 46.9 – 67.1) were tested on admission; overall, 96.8% of women had documented HBsAg test results. Among women without prenatal test documentation, the proportion tested on admission varied widely across states, ranging from 0% to 100%, with a median of 25%.

Prevalence of Maternal HBV Infection
Twenty-one women had documentation of a positive HBsAg prenatal test \( (n/18) \) or tested positive on admission \( (n/3) \) for an overall weighted prevalence of 0.9% (95% CI: 0.5–1.8). This prevalence estimate is based on test results for 96.8% of the sample; 174 women had neither documentation of a prenatal HBsAg test result nor a test on admission.

Management of Infants Who Were Born to Women With HBsAg-Positive and HBsAg-Unknown Status
Of the 18 infants who were born to HBsAg-positive women with a documented positive HBsAg prenatal test, 13 (67.1% [95% CI: 35.3–88.4]) received HepB within 12 hours of birth and 11 (62.1% [95% CI: 31.8–85.2]) received both HBIG and HepB within 12 hours. Two infants (13.7% [95% CI: 2.4–51.1]) did not receive HepB, and 5 infants (19.7% [95% CI: 5.3–51.8]) did not receive HBIG before discharge.

Among 320 infants who were born to women without documented prenatal HBsAg test results, 150 (52.4% [95% CI: 39.5–64.9]) were vaccinated within 12 hours of birth and 67 (20.1% [95% CI: 11.0–33.8]) were not vaccinated before discharge. Only 4 (1.9% [95% CI: 0.4–8.5]) of 41 infants who weighed <2000 g and were born to women of unknown HBsAg status received HBIG (Table 3).

Documentation of Maternal HBsAg Status and Discrepant Test Results
Table 4 provides data for 27 women with a documented HBsAg positive test result from any source. In 15 cases, the maternal test results in the infant medical record were discrepant or missing.

Universal Newborn HepB Vaccination
Overall, 68.7% (95% CI: 59.4–76.6) of infants received HepB at birth. Most strongly associated with vaccine administration was having a written hospital policy for HepB administration at birth and hospital location in a state with a universal birth dose policy. Other significant factors included maternal insurance carrier (Medicaid), hospital affiliated with a medical residency program, and rural location (Table 5).
In 3 states had high testing rates for such women, including those in Texas, where testing of all women who present for delivery is mandated. Reasons for the high testing rates in the 2 other states are unclear.

Management of HBV-exposed infants and infants born to women with unknown HBsAg status was suboptimal in this study. For HBV-exposed infants, comparisons with past studies are difficult because the number of HBV-exposed infants in this study and others is small. In the study by Yusuf et al.,13 9 of 12 exposed infants were vaccinated and 8 of 12 received HBlG (timing unspecified). In the study by Pierce et al.,10 7 of 9 were vaccinated within 24 hours (HBlG administration not reported). Administration of HepB to infants who were born to women with unknown HBsAg status was higher in this study than in that reported by Yusuf et al (22%). Administration of HBIG to infants who weighed <2000 g and were born to women with unknown status was very low in this study. Whereas the American Academy of Pediatrics has recommended that these infants receive HBlG since 1997,15 the ACIP adopted the recommendation only in 2005.4

Errors in the transcription of maternal HBsAg status have been well documented; as a result, the revised 2005 ACIP statement recommends that a copy of the original laboratory report indicating HBsAg status be included in both the maternal and infant medical records. Of the 27 mother–infant pairs in our sample with any documentation of a positive maternal HBsAg test result (Table 4), maternal results in the infant medical records were discrepant or missing for 15, demonstrating a medical documentation error rate of >50%. This is alarming, particularly when one considers that these errors were identified only among mother–infant pairs with any documentation of

### TABLE 4 Documentation of Maternal HBsAg Status: Comparison of Prenatal Test Results, Results of Tests Performed on Admission to Labor and Delivery Unit, and Test Results as Documented in Infant’s Medical Record for 27 Mother–Infant Pairs With Any Mention of Positive Maternal HBsAg Test Results

<table>
<thead>
<tr>
<th>Prenatal HBsAg Test Result (Maternal Record)</th>
<th>Maternal HBsAg Status (Infant Record)</th>
<th>n</th>
<th>No. of Infants Who Received HepB</th>
<th>No. of Infants Who Received HBIG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positivea, b Not documented</td>
<td>Positive</td>
<td>12</td>
<td>10</td>
<td>2c</td>
</tr>
<tr>
<td>Positivea, b Not documented</td>
<td>Not documented</td>
<td>3</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>Not documented</td>
<td>3</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Not documented</td>
<td>Negative</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Positivea, b Not documented</td>
<td>Negative</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Positivea, b Not documented</td>
<td>Negative</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

* a Cases included in estimate of percentage of mothers infected.
* b Cases included in Table 3, infants who were born to HBsAg-positive mothers.
* c Includes 1 infant who received birth dose but for whom time of receipt was not documented.

### DISCUSSION

We conducted a national survey of hospitals to determine policies for prevention of perinatal HBV transmission and conducted medical record reviews for almost 5000 mother–infant pairs. Our findings document gaps in prevention of perinatal HBV transmission that illustrate the importance of fully implementing the 2005 ACIP recommendations to prevent perinatal HBV transmission. Although prenatal HBsAg screening rates are high and consistent with past studies conducted in selected areas,10–12 they could be improved among selected groups, including black and Hispanic individuals and those who have Medicaid. Furthermore, substantial gaps exist for hospital policies aimed at preventing perinatal HBV transmission. In addition, gaps exist in hospital practices for testing women who are admitted with unknown status and managing infants who are born to mothers with an HBsAg-positive or unknown test result.

Policies that are specific to various aspects of prevention of perinatal HBV transmission were absent in up to one third of hospitals. Previous national data on policies examined in this survey are available only for screening of women who present with unknown status. Two studies conducted in 1993 estimated that 51% and 56% of hospitals had policies to perform HBsAg testing of women with unknown status, as compared with the 63% of hospitals in this survey.15,14 Data from the medical record review showed that the presence of policies was not uniformly associated with the outcome targeted by the policy. Specifically, although administration of HepB to all newborns was significantly associated with having a hospital policy for newborn vaccination, no association was observed for administration of HepB to infants who were born to women of unknown HBsAg status, and a nonsignificant association was observed for testing pregnant women on admission without documentation of prenatal HBsAg test results. This lack of consistency reflects gaps in implemented policies and highlights the importance of monitoring clinical practices and assessing performance indicators through hospital-based quality assurance reviews.

With respect to screening practices, although screening prenatally has become the norm, this is not true for screening women who are admitted without documented prenatal HBsAg results. A small proportion of women are admitted without test results and are not tested on admission. Hospitals

---

Hepatitis B: What Hospitals Need to Do to Protect Newborns  www.immunize.org/protect-newborns

80
TABLE 5 Factors Associated With Newborn Hepatitis B Vaccination

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Newborns Who Received Vaccine</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N (%)</td>
<td></td>
</tr>
<tr>
<td>Mother’s race/ethnicity</td>
<td></td>
<td>5000</td>
</tr>
<tr>
<td>White non-Hispanic</td>
<td>1917/2710</td>
<td>65.7</td>
</tr>
<tr>
<td>Black non-Hispanic</td>
<td>457/541</td>
<td>75.8</td>
</tr>
<tr>
<td>Asian</td>
<td>96/128</td>
<td>63.2</td>
</tr>
<tr>
<td>Hispanic</td>
<td>449/626</td>
<td>72.6</td>
</tr>
<tr>
<td>Other/unknown</td>
<td>329/450</td>
<td>65.4</td>
</tr>
<tr>
<td>Insurance status</td>
<td></td>
<td>0.01</td>
</tr>
<tr>
<td>Private</td>
<td>1510/2163</td>
<td>62.2</td>
</tr>
<tr>
<td>Medicaid</td>
<td>1468/1916</td>
<td>75.3</td>
</tr>
<tr>
<td>Other/unknown</td>
<td>270/376</td>
<td>67.1</td>
</tr>
<tr>
<td>Maternal age at time of infant birth, y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;18</td>
<td>125/157</td>
<td>70.8</td>
</tr>
<tr>
<td>18–25</td>
<td>1479/1959</td>
<td>71.7</td>
</tr>
<tr>
<td>26–30</td>
<td>845/1179</td>
<td>65.7</td>
</tr>
<tr>
<td>≥51</td>
<td>788/1141</td>
<td>67.5</td>
</tr>
<tr>
<td>Hospital has written policy for universal</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>dose of birth HepB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>2549/2910</td>
<td>87.2</td>
</tr>
<tr>
<td>No</td>
<td>862/1120</td>
<td>58.4</td>
</tr>
<tr>
<td>No. of births per year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;350</td>
<td>831/1106</td>
<td>74.5</td>
</tr>
<tr>
<td>≥350 and &lt;700</td>
<td>869/1178</td>
<td>76.5</td>
</tr>
<tr>
<td>≥700 and &lt;2000</td>
<td>858/1053</td>
<td>75.9</td>
</tr>
<tr>
<td>≥2000</td>
<td>710/1118</td>
<td>65.8</td>
</tr>
<tr>
<td>Highest level of neonatal care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic care</td>
<td>1564/2119</td>
<td>64.1</td>
</tr>
<tr>
<td>Specialty care</td>
<td>995/1379</td>
<td>65.1</td>
</tr>
<tr>
<td>Subspecialty care (neonatal intensive care)</td>
<td>664/932</td>
<td>72.5</td>
</tr>
<tr>
<td>Attending provider</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OBGYN</td>
<td>2406/3265</td>
<td>69.2</td>
</tr>
<tr>
<td>Family physician</td>
<td>517/704</td>
<td>68.9</td>
</tr>
<tr>
<td>Other/unknown</td>
<td>325/486</td>
<td>64.9</td>
</tr>
<tr>
<td>Hospital contains medical residency program</td>
<td></td>
<td>0.01</td>
</tr>
<tr>
<td>Yes</td>
<td>708/945</td>
<td>80.4</td>
</tr>
<tr>
<td>No</td>
<td>2040/3510</td>
<td>61.8</td>
</tr>
<tr>
<td>Hospital geographic location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rural</td>
<td>1513/1884</td>
<td>81.6</td>
</tr>
<tr>
<td>Urban</td>
<td>1935/2771</td>
<td>67.2</td>
</tr>
<tr>
<td>Hospital funding type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>For profit</td>
<td>400/548</td>
<td>65.0</td>
</tr>
<tr>
<td>Not for profit</td>
<td>2848/3909</td>
<td>70.0</td>
</tr>
<tr>
<td>State with universal birth dose supply policy</td>
<td></td>
<td>0.001</td>
</tr>
<tr>
<td>Yes</td>
<td>1718/2155</td>
<td>85.9</td>
</tr>
<tr>
<td>No</td>
<td>1461/2225</td>
<td>57.9</td>
</tr>
<tr>
<td>Total</td>
<td>3248/4455</td>
<td>68.7</td>
</tr>
</tbody>
</table>

*a* Totals may vary; missing and “don’t know” responses were excluded.

1 Policy to provide the newborn HepB dose at no cost to all infants, regardless of insurance status.

2 Infants who weighed <2000 g at birth and were born to HBsAg-negative mothers were excluded.

A positive maternal HBsAg test result and thus may represent only more readily identified errors. It is possible that additional HBsAg documentation errors could be discovered among mother–infant pairs without any documentation of a positive HBsAg test result where positive test results were consistently documented as negative or omitted altogether; however, uncovering these types of errors are more labor-intensive. As expected, a minority (16%) of hospitals documented maternal HBsAg status by placing a copy of the original laboratory report in the medical record. Infants who were born to women with inconsistencies in documented HBsAg status were less likely to receive prophylaxis, which has been reported previously.

The strongest predictor of newborn HepB receipt was having a written hospital policy for HepB administration at birth, highlighting the importance of such policies. Newborn HepB coverage was higher in this study (68%) than that reported in the 2007 National Immunization Survey (NIS) where 53.2% of newborns were vaccinated by the third day of life.

Infants who were included in the 2007 NIS were born January 2004 through June 2006, and infants who were included in this study were born January 2005 through December 2006. A potential reason for the difference between these 2 estimates is that this study included data that were collected directly from infant hospital medical records, whereas in the NIS, vaccination coverage was obtained from outpatient pediatric provider medical records. The latter might not always have records of hospital-administered HepB. Random error and systematic biases in either survey may also contribute to the differences.

The estimated HBsAg-positive prevalence among pregnant women in this assessment was 0.9% (95% CI: 0.5–1.8) compared with 0.4% (95% CI: 0.2–0.8) in the 1993 study; however, this difference is not statistically significant. Given differences in the proportion of mothers with known HBsAg status between the 2 assessments and discrepancies in HBsAg test result documentation discussed, ascertainment of true infection rate from a medical record review is challenging.

There is a growing need for implementation of perinatal HBV prevention practices by delivery hospitals given that the number of births to foreign-born women is increasing. In 2004, 24% of all US births were to foreign-born women compared with 18% in 1993. In addition, immigra-
tion from countries with high endemicity has increased.118 There are certain limitations to these findings. First, personnel who conducted data collection varied, with the majority of medical record abstractions conducted by health department staff and the remainder by hospital personnel. Second, although the overall response rate was high, 2 large states, California and Texas, had low hospital participation rates, which could affect the representativeness of the data. Third, this study was not designed to follow infants who were born to HBsAg-positive mothers to determine perinatal HBV infection rate.

CONCLUSIONS

Given the existence of highly effective PEP, perinatal HBV transmission can be almost entirely prevented, but gaps in the delivery hospital prevention policies and practices persist. Universal newborn HepB vaccination, together with timely administration of appropriate prophylaxis in infants who are born to HBsAg-positive women and women of unknown HBsAg status, are essential hospital clinical practices for preventing perinatal HBV infections. In October 2008, the National Quality Forum endorsed 2 perinatal care performance measures specific to HepB,19 1 to monitor hospital newborn HepB coverage and a second to monitor the proportion of infants who are born to HBsAg-positive women and receive timely and appropriate prophylaxis in delivery hospitals. Although use of National Quality Forum performance measures is a promising step toward closing the persistent hospital gaps for perinatal HBV prevention in the United States, considerable work remains.

ACKNOWLEDGMENTS

We extend sincere appreciation to the participating delivery hospitals and perinatal hepatitis B coordinators whose tireless public health efforts make perinatal hepatitis B prevention possible; John Stevenson, PhD (CDC, National Center for Immunization and Respiratory Diseases, Immunization Services Division, Atlanta, GA), and Shannon Stokley, MPH (CDC, National Center for Immunization and Respiratory Diseases, Immunization Services Division, Atlanta, GA), for dedicated data management efforts; Norma Allred, PhD, MSN (CDC, National Center for Immunization and Respiratory Diseases, Immunization Services Division, Atlanta, GA), and Laverne Graham, MPH (CDC, National Center for Immunization and Respiratory Diseases, Immunization Services Division, Atlanta, GA), for helpful editorial comments; and the CDC Division of Viral Hepatitis and Immunization Services Division for project concept and support.

REFERENCES

Gaps in Hospital Policies and Practices to Prevent Perinatal Transmission of Hepatitis B Virus

Bayo C. Willis, Pascale Wortley, Susan A. Wang, Lisa Jacques-Carroll and Fan Zhang

*Pediatrics* 2010;125:704; originally published online March 8, 2010;
DOI: 10.1542/peds.2009-1831
Additional Resources

**American Academy of Pediatrics and American College of Obstetricians and Gynecologists**

**Guidelines for Perinatal Care, 7th Edition**

This gold-standard resource is a one-stop problem-solver for hospital and birthing center professionals who need to know about the latest recommendations, policies, and best practices from the American Academy of Pediatrics (AAP) and the American College of Obstetricians and Gynecologists (ACOG). Chapter 10 (“Perinatal Infections,” pages 305–310) covers the detailed AAP and ACOG recommendations for preventing perinatal hepatitis B transmission.

To purchase, visit the ACOG website:


ACOG members are eligible for a discount.

**Centers for Disease Control and Prevention (CDC)**

**Information for Healthcare Professionals on Perinatal Hepatitis B Transmission**

CDC has compiled links to all of its resources for healthcare professionals about preventing perinatal hepatitis B transmission and made them available at

- [www.cdc.gov/hepatitis/HBV/PerinatalXmtn.htm](http://www.cdc.gov/hepatitis/HBV/PerinatalXmtn.htm)

**Protect Your Baby for Life: Hepatitis B and Your Baby**

A terrific 2-page Q&A handout from CDC helps healthcare professionals impress upon parents the importance of hepatitis B vaccination at birth. The online handout is suitable for either color or black-and-white printing and can be downloaded from

- [www.cdc.gov/hepatitis/HBV/PDFs/HepBPerinatal-ProtectHepBYourBaby.pdf](http://www.cdc.gov/hepatitis/HBV/PDFs/HepBPerinatal-ProtectHepBYourBaby.pdf)

**Testing for Hepatitis B Virus Infection During Pregnancy: Flowchart for Prenatal Providers**

A decision chart for properly testing pregnant women, reporting the results, and educating the patients.

- [www.cdc.gov/hepatitis/HBV/PDFs/PerinatalAlgorithm-Prenatal.pdf](http://www.cdc.gov/hepatitis/HBV/PDFs/PerinatalAlgorithm-Prenatal.pdf)